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I. INTRODUCTION
In previous work, I have accused the U.S. Food and Drug Adminis-
tration (FDA) of acting in a lawless fashion.1  In those articles, I fo-
cused on the agency’s efforts to evade constitutional constraints and
© Copyright held by the NEBRASKA LAW REVIEW
* Professor of Law, University of Florida; author of LAW, MEDICINE, AND MEDICAL
TECHNOLOGY: CASES & MATERIALS (3d ed. 2012).  In citations to legislative mater-
ials, the editors have graciously allowed me to deviate from Bluebook Rule 12.4(c)
by supplying additional information that more precisely identifies the location of
particular subsections.
1. See Lars Noah, The Little Agency That Could (Act with Indifference to Constitu-
tional and Statutory Strictures), 93 CORNELL L. REV. 901, 924 (2008) (“[O]ver the
course of a century of struggling to protect the public health with its limited stat-
utory powers and often inadequate resources, the FDA evidently has institution-
alized a practice of cavalierly ignoring legal constraints.”).
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statutory limits on its jurisdiction.2  Less often have I addressed the
seemingly more prosaic procedural irregularities in the way that the
FDA conducts itself, except insofar as these have allowed it to cross
substantive boundaries largely unnoticed.  Even if the agency never
strayed from the confines of its delegated authority, however, efforts
to circumvent procedural requirements can have serious consequences
for the quality of its work and those subject to its commands.  A pref-
erence for staying under the radar whenever possible means evading
critical checks exercised by all three branches of government.
The FDA has used a variety of procedural short cuts when imple-
menting its statutory powers.  Part II of this paper focuses on the
agency’s shift from the promulgation of binding rules to the issuance
of nonbinding guidance documents.  Although Congress and the White
House seem to have become increasingly comfortable with the
agency’s practice, the FDA may have gotten a little carried away with
this mechanism for announcing its policies.  Part III of this paper ex-
plains how the agency secures widespread adherence to its technically
nonbinding policies, whether expressed through guidance documents
or left largely unspoken.  The FDA enjoys significant leverage over
regulated entities, by virtue of its powers of enforcement and product
licensing, and in both settings it can communicate threats and offers
that (more often than not) secure “voluntary” compliance with
whatever the agency demands.  Even if the FDA limits itself to re-
questing concessions that it could have—after expending greater ef-
fort—imposed directly, such a backdoor approach sacrifices the
procedural safeguards dictated by the legislative, executive and judi-
cial branches.
II. ANNOUNCING AGENCY INTENTIONS
AND EXPECTATIONS
During the last quarter of a century, federal regulators have found
it increasingly difficult to promulgate regulations,3 and guidance doc-
2. See id. at 903, 917–25; see also Lars Noah, Regulating Cigarettes: (Non)sense and
Sensibility, 22 S. ILL. U. L.J. 677, 691 (1998) (arguing that the FDA “should not
be free to ignore the outer boundaries of its delegated authority in pursuit of a
well-meaning crusade against a public health problem”). See generally Lars
Noah, Interpreting Agency Enabling Acts: Misplaced Metaphors in Administra-
tive Law, 41 WM. & MARY L. REV. 1463, 1530 (2000) (“The rush to defend seem-
ingly desirable regulatory initiatives should not blind us to the potentially
serious institutional consequences of adopting a stance of excessive faith in ad-
ministrative agencies.”); id. at 1498 (“As creatures of statutes lacking any inde-
pendent constitutional pedigree, agencies cannot invoke some kind of inherent
authority to justify actions that find no warrant in their enabling legislation.”).
3. See Thomas O. McGarity, Some Thoughts on “Deossifying” the Rulemaking Pro-
cess, 41 DUKE L.J. 1385, 1386 (1992) (discussing “the increasingly stiff and for-
malized structures of the informal rulemaking process”); id. at 1462 (same). See
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uments have become a more frequently used format for announcing
agency intentions and expectations.4  Under the Administrative Pro-
cedure Act (APA),5 “interpretative rules” and “general statements of
policy” need not undergo notice-and-comment rulemaking,6 though
courts have struggled to draw a line between “legislative” and “nonleg-
islative” rules.7  Technically, guidance documents lack any binding ef-
fect,8 but agencies often seem to expect regulated entities to abide by
generally CORNELIUS M. KERWIN & SCOTT R. FURLONG, RULEMAKING: HOW GOV-
ERNMENT AGENCIES WRITE LAW AND MAKE POLICY (4th ed. 2010).  Commentators
continue to debate this question. Compare Jason Webb Yackee & Susan Webb
Yackee, Testing the Ossification Thesis: An Empirical Examination of Federal
Regulatory Volume and Speed, 1950–1990, 80 GEO. WASH. L. REV. 1414 (2012),
with Richard J. Pierce, Jr., Rulemaking Ossification Is Real: A Response to Test-
ing the Ossification Thesis, 80 GEO. WASH. L. REV. 1493 (2012).
4. See HOUSE COMM. ON GOV’T REFORM, NON-BINDING LEGAL EFFECT OF AGENCY
GUIDANCE DOCUMENTS, H.R. REP. NO. 106-1009, at 5 (2000) (finding that just
three federal agencies had generated over 5,500 guidance documents during the
late 1990s); see also id. at 1 (criticizing such “backdoor” regulation as “an abuse of
power”).
5. Pub. L. No. 79-404, 60 Stat. 237 (1946) (codified as amended at 5 U.S.C.
§§ 551–559, 701–706 (2012)).
6. See 5 U.S.C. § 553(b)(A) (2012); Robert A. Anthony, A Taxonomy of Federal
Agency Rules, 52 ADMIN. L. REV. 1045 (2000); William Funk, A Primer on Nonleg-
islative Rules, 53 ADMIN. L. REV. 1321, 1322–35 (2001); see also McGarity, supra
note 3, at 1393 (“Perhaps more troublesome to the goals of open government is
the increasing tendency of agencies to engage in ‘nonrule rulemaking’ through
relatively less formal devices such as policy statements, interpretative rules,
manuals, and other informal devices.”); id. at 1441–43 (same).  Technically, one
should not contrast guidance-making with rulemaking; instead, the former repre-
sents a subset of the latter—guidance-making is a form of (exempt) rulemaking
under the APA. See 5 U.S.C. § 551(4)&(5) (2012).  Moreover, after passage of the
Freedom of Information Act (FOIA), Pub. L. No. 89-487, 80 Stat. 250 (1966) (codi-
fied as amended at 5 U.S.C. § 552 (2012)), agencies have incentives to publish
otherwise exempt rules, see 5 U.S.C. § 552(a)(1)(D), (2)(B) (2012); see also infra
note 8 (discussing the publication of exempt rules and their effect).
7. For recent surveys of the extensive case law and academic commentary on this
question, see David L. Franklin, Legislative Rules, Nonlegislative Rules, and the
Perils of the Short Cut, 120 YALE L.J. 276 (2010); Stephen M. Johnson, In Defense
of the Short Cut, 60 U. KAN. L. REV. 495, 509–35 (2012); Morgan Douglas Mitch-
ell, Note, Wolf or Sheep?: Is an Agency Pronouncement a Legislative Rule, Inter-
pretive Rule, or Policy Statement?, 62 ALA. L. REV. 839 (2011).
8. See Jacob E. Gersen, Legislative Rules Revisited, 74 U. CHI. L. REV. 1705,
1708–13 (2007); id. at 1705 (“The distinction between legislative rules and non-
legislative rules is one of the most confusing in administrative law. . . .  To de-
scribe the legislative rule debate is to conjure doctrinal phantoms, circular
analytics, and fundamental disagreement even about correct vocabulary.”).
When published, however, exempt rules may have an intermediate (precedential)
effect. See Peter L. Strauss, Publication Rules in the Rulemaking Spectrum: As-
suring Proper Respect for an Essential Element, 53 ADMIN. L. REV. 803, 806, 824,
828–33, 843, 849–50 (2001); see also id. at 811 (“[A]ctions validly adopted pursu-
ant to congressionally authorized rulemaking procedures have the kind of au-
thority we commonly ascribe to statutes; actions that meet the publication
requirements of section 552(a) have such authority as we commonly ascribe to
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announcements that have not emerged from rulemaking procedures.9
In addition to avoiding the need to follow procedural requirements
under the APA, agencies may shy away from issuing legislative rules
in order to dodge judicial review.10  More recently, one commentator
suggested that avoidance of scrutiny by the White House’s Office of
Management and Budget (OMB) also may serve as a motivating fac-
tor.11  As another commentator summarized:
precedents; and in other cases, agencies are not permitted to treat their actions
as having legal force on citizens.”); id. at 816 (“Nothing in the APA permits an
agency to claim legislative force for a publication rule.”).
9. See Robert A. Anthony, Interpretive Rules, Policy Statements, Guidances, Manu-
als, and the Like—Should Federal Agencies Use Them to Bind the Public?, 41
DUKE L.J. 1311, 1315 (1992) (“While these nonlegislative rules by definition can-
not legally bind, agencies often inappropriately issue them with the intent or ef-
fect of imposing a practical binding norm upon the regulated or benefited
public.”); Yackee & Yackee, supra note 3, at 1432 (“[A]gencies may be able to
regulate via non-rule rules with relative impunity.”); Cindy Skrzycki, Finding a
Way to Better Guidance, WASH. POST, Dec. 20, 2005, at D1 (“Though not legally
binding, guidance is sometimes considered practically binding by regulated in-
dustries, a sort of ‘backdoor’ rulemaking.”).  Guidance documents represent a
form of “soft law.” See Jacob E. Gersen & Eric A. Posner, Soft Law: Lessons from
Congressional Practice, 61 STAN. L. REV. 573, 576–77 (2008).
10. Courts typically find challenges to nonlegislative rules unripe. See Nat’l Park
Hospitality Ass’n v. Dep’t of Interior, 538 U.S. 803, 809–12 (2003); Colwell v.
HHS, 558 F.3d 1112, 1123–29 (9th Cir. 2009); Munsell v. USDA, 509 F.3d 572,
585–87 (D.C. Cir. 2007); Funk, supra note 6, at 1335–41; Gwendolyn McKee, Ju-
dicial Review of Agency Guidance Documents: Rethinking the Finality Doctrine,
60 ADMIN. L. REV. 371, 385–91, 400–02, 407 (2008).  If an agency uses a guidance
document in the course of imposing a sanction or otherwise seeks to give it a
binding effect, then a court would entertain a procedural or other objection to
that announcement. See, e.g., NRDC v. EPA, 643 F.3d 311, 320–21 (D.C. Cir.
2011); Manufactured Housing Inst. v. EPA, 467 F.3d 391, 397–99 (4th Cir. 2006).
So long as agencies take care and rely on indirection, however, courts generally
will decline to review guidance documents.  Pre-enforcement challenges might
have a better chance of surmounting finality and ripeness obstacles if interested
parties first filed a petition with the agency requesting the amendment or revoca-
tion of a nonlegislative rule and then seek judicial review of the denial. See Sean
Croston, The Petition Is Mightier Than the Sword: Rediscovering an Old Weapon
in the Battles over “Regulation Through Guidance,” 63 ADMIN. L. REV. 381,
394–99 (2011); see also Fox Television Stations, Inc. v. FCC, 280 F.3d 1027, 1037
(D.C. Cir. 2002) (“[D]enial of a petition to initiate a rulemaking for the repeal or
modification of a rule is a final agency action subject to judicial review.”).
11. See Jennifer Nou, Agency Self-Insulation Under Presidential Review, 126 HARV.
L. REV. 1755, 1784–86 (2013); see also Nina A. Mendelson & Jonathan B. Wiener,
Responding to Agency Avoidance of OIRA, 37 HARV. J.L. & PUB. POL’Y 447,
485–89 (2014) (assessing this claim); Robert Pear, Bush Directive Increases His
Regulatory Sway, N.Y. TIMES, Jan. 30, 2007, at A1 (“[OMB] already has an elabo-
rate process for the review of proposed rules. But in recent years, many agencies
have circumvented this process by issuing guidance documents . . . .”).  OMB re-
views “significant” proposed and final rules before publication. See Exec. Order
No. 12,866, Regulatory Planning and Review, §§ 3(f), 6(a)(3), 58 Fed. Reg. 51,735
(Oct. 4, 1993), amended by Exec. Order No. 13,563, Improving Regulation and
Regulatory Review, 76 Fed. Reg. 3821 (Jan. 18, 2011), reprinted in 5 U.S.C. § 601
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[B]y issuing a guidance document, an agency can obtain a rule-like effect
while minimizing political oversight and avoiding the procedural discipline,
public participation, and judicial accountability required by the APA.  The
prospect of “compliance for less” is almost certainly among the reasons that
agencies use guidance documents rather than go through the effort of notice-
and-comment rulemaking.12
This Part offers an in-depth look at the evolving use of guidance docu-
ments by the FDA.13
app. (2012).  OMB did, however, at one point insist on reviewing significant gui-
dance documents, and it evidently (though informally) continues to do so. See
infra notes 94–98 and accompanying text.  The Office of Information and Regula-
tory Affairs (OIRA)—a division of OMB—carries out these functions. See Cass R.
Sunstein, The Office of Information and Regulatory Affairs: Myths and Realities,
126 HARV. L. REV. 1838 (2013); Note, OIRA Avoidance, 124 HARV. L. REV. 994,
994–1003 (2011).
12. Nina A. Mendelson, Regulatory Beneficiaries and Informal Agency Policymaking,
92 CORNELL L. REV. 397, 408 (2007) (adding that, “[s]ince guidance documents
are generally not published in the Federal Register, they are also less likely to be
subject to congressional oversight or attention in the media” (footnote omitted));
see also id. at 410–13 (elaborating on the reasons why guidance documents
largely escape executive, legislative, and judicial review); id. at 452 (“When an
agency chooses to issue a policy in a guidance document rather than a rule, regu-
latory beneficiaries lose the crucial ability to participate in the agency decision
and to obtain judicial review of it.”); cf. Anthony, supra note 9, at 1318; id. at
1379 (“[I]f an agency wants to bind the public, it . . . should not try to do it on the
cheap or on the sly.”).
13. For similar case studies involving other agencies, see Jill E. Family, Easing the
Guidance Document Dilemma Agency by Agency: Immigration Law and Not Re-
ally Binding Rules, 47 U. MICH. J.L. REFORM 1 (2013); Kristin E. Hickman, Color-
ing Outside the Lines: Examining Treasury’s (Lack of) Compliance with
Administrative Procedure Act Rulemaking Requirements, 82 NOTRE DAME L. REV.
1727 (2007); Sam Kalen, The Transformation of Modern Administrative Law:
Changing Administrations and Environmental Guidance Documents, 35 ECOL-
OGY L.Q. 657 (2008).  In contrast, a recent empirical study confidently concluded
that we have nothing to worry about. See Connor N. Raso, Note, Strategic or
Sincere? Analyzing Agency Use of Guidance Documents, 119 YALE L.J. 782,
805–23 (2010); see also id. at 805 (including the FDA as one of five agencies sur-
veyed for purposes of considering all guidance documents issued relative to legis-
lative rules promulgated annually over a ten-year period).  Even if his conclusion
follows from the data that he reviewed, my unapologetically qualitative survey of
the practice at one agency begs to differ. Cf. id. at 821–22 & n.170 (conceding
that the FDA may represent a special case); id. at 811 n.140, 816 n.156 (finding
no compilation of FDA guidance documents deemed “significant” under OMB’s
criteria).  For another seemingly tone-deaf empirical assessment of the issue, see
Yackee & Yackee, supra note 3, at 1438–39, 1460–64 (offering an admittedly
crude survey focusing on the Department of Interior (DOI) that generally echoed
Raso’s conclusion); id. at 1474 (summarizing interviews with DOI employees
about their utilization of nonlegislative rules).  Remarkably, these authors
searched for nonlegislative rules by identifying uncommented upon announce-
ments in the “Rules and Regulations” section of the Federal Register. See id. at
1461 & n.229.  That would pick up direct final rules, and technically it coincides
with the categorization used by the Office of Federal Register, see 1 C.F.R.
§ 5.9(b) (2014), but in practice most announcements of nonlegislative rules ap-
pear in the separate “Notices” section, see id. § 5.9(d).
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A. The FDA’s Struggles in Promulgating Regulations
The FDA was one of the first federal agencies to make extensive
use of its initially unclear rulemaking powers.  In lieu of bringing en-
forcement actions under the open-ended provisions of the Food, Drug,
and Cosmetic Act (FDCA),14 and generating adjudicatory precedent
for future cases, the FDA began to promulgate more detailed rules to
implement its statutory authority.15  Although infractions still re-
quired individual enforcement proceedings, the agency would simplify
its burden of proof in those cases,16 which, coupled with the greater
clarity of expectations, would help to promote improved compliance.
In the FDCA, Congress expressly granted the agency the authority
to issue regulations governing certain subjects,17 but it also required
that interested parties be allowed to request a public hearing as part
of the rulemaking process.18  Until 2007, for instance, the FDA’s
power to promulgate prescription drug advertising regulations was
subject to this “formal” rulemaking procedure.19  In practice, these
procedural requirements became a source of frustrating delays for the
agency.20
The statute also included residual rulemaking authority.21  After
courts decided that this provision empowered the FDA to issue bind-
ing regulations on matters not specifically covered by the formal
14. Pub. L. No. 75-717, 52 Stat. 1042 (1938) (codified as amended at 21 U.S.C.
§§ 301–399d (2012)).
15. See Eric R. Claeys, The Food and Drug Administration and the Command-and-
Control Model of Regulation, 49 ST. LOUIS U. L.J. 105, 117–21 (2004); Richard A.
Merrill, FDA and the Effects of Substantive Rules, 35 FOOD DRUG COSM. L.J. 270,
271–72 (1980); Reuel E. Schiller, Rulemaking’s Promise: Administrative Law and
Legal Culture in the 1960s and 1970s, 53 ADMIN. L. REV. 1139, 1147–49 (2001).
16. See generally Charles C. Ames & Steven C. McCracken, Framing Regulatory
Standards to Avoid Formal Adjudication: The FDA as a Case Study, 64 CAL. L.
REV. 14 (1976).
17. See 21 U.S.C. § 371(e) (2012).
18. See Pharm. Mfrs. Ass’n v. Gardner, 381 F.2d 271, 278 (D.C. Cir. 1967).
19. See 21 U.S.C. § 352(n) (2006), amended by Food and Drug Administration
Amendments Act of 2007, Pub. L. No. 110-85, § 901(d)(6), 121 Stat. 823, 942.  Evi-
dently Congress had become frustrated by the agency’s failure to undertake any
rulemaking in this area since the late 1960s. See infra notes 105–06 and accom-
panying text.
20. See Robert W. Hamilton, Rulemaking on a Record by the Food and Drug Admin-
istration, 50 TEX. L. REV. 1132, 1142 (1972) (“[T]he FDA has conducted two major
[formal rulemaking] proceedings that have been the subject of wide criticism.
Both proceedings have taken (or will take) more than ten years from the formula-
tion of the original proposal to the actual effective date of the regulation.”); cf.
Aaron L. Nielson, In Defense of Formal Rulemaking, 75 OHIO ST. L.J. 237
(bemoaning the fact that this procedure has fallen into disuse, and suggesting
that the delays experienced by the FDA arose from its failure to manage the pro-
cess efficiently).
21. See 21 U.S.C. § 371(a).
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rulemaking provision,22 the agency shifted to notice-and-comment
procedures for the promulgation of rules.  At the same time, courts
allowed interested parties to bring pre-enforcement challenges to such
regulations.23  Although “informal” rulemaking avoided the cumber-
some hearings required with formal rulemaking, searching judicial re-
view on the merits,24 coupled with increasing procedural demands
added by all three branches of government, have made it increasingly
difficult.25  For instance, in the FDA’s largest rulemaking exercise un-
derway at the moment (regulations to implement significant statutory
amendments related to food safety), OMB apparently delayed issu-
ance of the proposed rules for over one year.26
22. See Nat’l Ass’n Pharm. Mfrs. v. FDA, 637 F.2d 877 (2d Cir. 1981); Pharm. Mfrs.
Ass’n v. FDA, 634 F.2d 106, 108 (3d Cir. 1980) (per curiam); Thomas W. Merrill &
Kathryn Tongue Watts, Agency Rules with the Force of Law: The Original Con-
vention, 116 HARV. L. REV. 467, 557–65 (2002); see also id. at 513–16, 583–84,
586–87 (arguing that these decisions reflect a fundamental misinterpretation of
the FDCA, though conceding that any effort now to correct this mistake would
imperil many of the legislative rules issued by the FDA).
23. See Abbott Labs. v. Gardner, 387 U.S. 136 (1967) (holding that an FDA drug
labeling regulation was ripe for judicial review).
24. For a classic illustration involving the FDA, see United States v. Nova Scotia
Food Prods. Corp., 568 F.2d 240, 249–53 (2d Cir. 1977).
25. See U.S. GEN. ACCT. OFFICE, GAO/HRD-92-35, FDA REGULATIONS: SUSTAINED
MANAGEMENT ATTENTION NEEDED TO IMPROVE TIMELY ISSUANCE (1992); Thomas
J. Hwang et al., Quantifying the Food and Drug Administration’s Rulemaking
Delays Highlights the Need for Transparency, 33 HEALTH AFF. 309, 313 (2014)
(discussing “[t]he slow pace of FDA rulemaking”); see also supra note 3 (referenc-
ing the ossification literature).
26. See Brady Dennis, Sweeping Rules for Food Are Released, WASH. POST, Jan. 5,
2013, at A1 (“The new proposals spent more than a year awaiting final approval
from the OMB.  That led some stakeholders to speculate that the administration
might have been holding up the proposals until after the election.”); see also Ctr.
for Food Safety v. Hamburg, 954 F. Supp. 2d 965, 970–72 (N.D. Cal. 2013) (find-
ing that the FDA had violated deadlines for the issuance of seven different sets of
regulations to implement the Food Safety Modernization Act); U.S. GOV’T AC-
COUNTABILITY OFFICE, GAO-09-205, FEDERAL RULEMAKING: IMPROVEMENTS
NEEDED TO MONITORING AND EVALUATION OF RULES DEVELOPMENT AS WELL AS TO
THE TRANSPARENCY OF OMB REGULATORY REVIEWS 82 (2009) (discussing the fate
of an FDA regulation as one of several case studies examined); Sabrina
Tavernise, F.D.A. Sets a Standard on Labeling “Gluten Free,” N.Y. TIMES, Aug. 3,
2013, at A11 (reporting that the agency finally issued this regulation six years
after first proposing it, and nine years after Congress had specifically demanded
such rulemaking).  Similarly, OMB evidently delayed the release of a final rule
from the Centers for Medicare and Medicaid Services (CMS) to implement the so-
called “sunshine” provisions of the Affordable Care Act, which require the disclo-
sure of pharmaceutical and medical device industry gifts to physicians. See Edi-
torial, In the Dark on Doctor Perks, L.A. TIMES, Feb. 1, 2013, at A16 (“[T]he
regulations are 15 months overdue. As with the new food-safety act regulations—
most of which were finally released in January, a full year past deadline—the
sunshine rules . . . have been held up by [OMB].”).
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The FDA has experimented with further short cuts for issuing
rules.  In 1997, expressing an interest in expediting the issuance of its
routine or otherwise noncontroversial regulations, the agency pub-
lished a guidance document to describe “direct final rulemaking,”
which dispenses with the need to publish a proposal or invite public
comment unless someone objects shortly after promulgation.27  Direct
final rulemaking has not, however, worked out as well as the agency
had hoped.  A survey conducted a little more than one year after issu-
ance of the guidance found that “the FDA has issued thirteen direct
final rules, five of which it has already withdrawn in whole or in part
because of the receipt of some significant adverse comment.”28  One
decade later, a follow-up survey found a similar pattern,29 and little
has changed during the latest five-year period.30
27. See Notice, Guidance for FDA and Industry: Direct Final Rule Procedures, 62
Fed. Reg. 62,466 (Nov. 21, 1997).  The FDA announced that it would ordinarily
provide a post-promulgation comment period of at least seventy-five days after
publishing a direct final rule, and, no more than thirty days after the close of this
period, it would publish a notice either confirming an effective date of thirty days
thereafter or announcing the withdrawal of the rule because of the receipt of sig-
nificant adverse comment. See id. at 62,468.  In tandem with the initial publica-
tion of a direct final rule, the FDA promised to issue a companion notice of
proposed rulemaking (NPRM), which would then provide the basis for proceeding
with informal rulemaking in the event that the agency withdrew the direct final
rule, and any comments previously received would be considered in the course of
this parallel rulemaking proceeding. See id. at 62,469.
28. Lars Noah, Doubts About Direct Final Rulemaking, 51 ADMIN. L. REV. 401, 411 &
n.47 (1999) (contrasting this initial pattern with the greater success experienced
by the Environmental Protection Agency (EPA) and others, adding that “dispari-
ties in agency batting averages will affect their relative success in realizing the
supposed efficiencies of direct final rulemaking”); see also id. at 412–28 (explain-
ing why the procedure is unlawful); id. at 423 (suggesting that courts “might re-
sist direct final rulemaking as an inappropriate dodge”); id. at 426 (“[T]o the
extent that regulations promulgated through direct final rulemaking seem vul-
nerable to procedural or substantive challenges, this expedited process may actu-
ally backfire by increasing the odds of challenges to non-controversial rules that
regulated entities would otherwise not bother assailing in court.”).
29. See Michael Kolber, Rulemaking Without Rules: An Empirical Study of Direct
Final Rulemaking, 72 ALB. L. REV. 79 (2009).  Excluding entries from his survey
that I already had counted (i.e., through 3/15/99), Kolber’s Appendix showed that
the FDA had issued twenty-five direct final rules and nine notices of withdrawal.
See id. at 113–15.
30. During this period, the FDA issued twelve direct final rules and four notices of
withdrawal.  These numbers are based on a Lexis search (conducted 6/25/13) in
the “Federal Register” library for “agency(FDA) and action(direct w/1 final) and
date aft May 1, 2008” and exclude confirmation notices.
2014] GOVERNANCE BY THE BACKDOOR 97
B. Guidance-making as the New Rulemaking
As informal rulemaking became increasingly difficult, the FDA
shifted from promulgating regulations to issuing guidance.31  By the
mid-1990s, “[w]ell over a thousand such documents exist[ed].”32  This
offered the agency a convenient short cut for communicating its expec-
tations to regulated entities, but the FDA’s growing dependence on
guidance documents presents a couple of problems.  First, these infor-
mal announcements may operate as de facto rules but escape normal
procedural safeguards for their promulgation or review.33  Second,
they allow the FDA to take positions that do not even constrain
agency officials, which leaves regulated entities guessing about their
rights and obligations.34  Nonetheless, Congress largely has endorsed
and even encouraged this development, though questions remain
about whether the agency may have gone too far.
1. Evolution of the FDA’s Good Guidance Practices
The FDA has formalized its procedures for the issuance and use of
guidance documents. In 1997, the agency announced its policy on
“Good Guidance Practices” (GGPs).35  The new policy called for uni-
31. See Todd D. Rakoff, The Choice Between Formal and Informal Modes of Adminis-
trative Regulation, 52 ADMIN. L. REV. 159, 168 (2000).  Actually, it had done so
throughout its history, though the nomenclature has changed over time. See
K.M. Lewis, Informal Guidance and the FDA, 66 FOOD & DRUG L.J. 507, 509–23
(2011) (tracing the evolution in the agency’s use of guidance); id. at 538–43 (sum-
marizing the advantages and disadvantages of the FDA’s growing reliance on
guidance documents, concluding that the practice is generally beneficial); id. at
546 (“The story of guidance at FDA is full of twists and turns.  After a century of
experimentation, FDA has stumbled upon a formula that reasonably accommo-
dates the conflicting interests of stakeholders.”).
32. Request for Comments, Guidance Documents; The Food and Drug Administra-
tion’s Development and Use, 61 Fed. Reg. 9181, 9182 (Mar. 7, 1996).
33. See Syncor Int’l Corp. v. Shalala, 127 F.3d 90, 95–96 (D.C. Cir. 1997); Cmty. Nu-
trition Inst. v. Young, 818 F.2d 943, 948–49 (D.C. Cir. 1987) (per curiam); Bel-
larno Int’l, Ltd. v. FDA, 678 F. Supp. 410, 414–16 (E.D.N.Y. 1988); Edward John
Allera, FDA’s Use of Guidelines, Notices of Proposed Rulemaking, and Compli-
ance Policies as De Facto Rules: An Abuse of Discretion, 36 FOOD DRUG COSM. L.J.
270, 274–77 (1981); Rakoff, supra note 31, at 167 (“If an agency . . . generates a
set of detailed guidelines for its inspectors to enforce, it in effect still establishes
the law for all those unwilling to pay the expense, or suffer the ill-will of challeng-
ing the agency in court.”); James Hunnicutt, Note, Another Reason to Reform the
Federal Regulatory System: Agencies’ Treating Nonlegislative Rules as Binding
Law, 41 B.C. L. REV. 153, 164, 175 (1999).
34. See Lars Noah, The FDA’s New Policy on Guidelines: Having Your Cake and Eat-
ing It Too, 47 CATH. U. L. REV. 113, 140–42 (1997) (criticizing the agency’s prac-
tice of not taking definitive positions in guidance documents and, thereby,
attempting to escape judicial review).
35. See Notice, The Food and Drug Administration’s Development, Issuance, and Use
of Guidance Documents, 62 Fed. Reg. 8961 (Feb. 27, 1997).  Less than a year
earlier, the FDA had published a notice of its proposed policy, inviting comments
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formity in format, the use of standardized nomenclature, explicit lan-
guage disavowing any binding legal effect, assurances of access to
these documents by interested parties, limited opportunities for public
input, and procedures for internal review.36  This policy represented a
response to complaints that the FDA inappropriately used guidance
documents as if they constituted binding rules that regulated entities
had to follow.37
Less than a year later, in the course of making sweeping amend-
ments to the FDCA, Congress directed the agency to issue the GGPs
as regulations no later than July 1, 2000.38  Although it generally en-
dorsed the FDA’s growing reliance on guidance documents, Congress
also took the opportunity to impose some restrictions on their develop-
ment and use.39  The amendment reiterated the nonbinding character
and announcing a public meeting on the subject. See Request for Comments,
Guidance Documents; The Food and Drug Administration’s Development and
Use, 61 Fed. Reg. 9181 (Mar. 7, 1996); Notice of Public Meeting, Guidance Docu-
ments; The Food and Drug Administration’s Development and Use, 61 Fed. Reg.
15,080 (Apr. 4, 1996).
36. See 62 Fed. Reg. at 8968–70; see also Hunnicutt, supra note 33, at 179–85, 192
(describing and critiquing aspects of the FDA’s original GGPs policy).
37. See 62 Fed. Reg. at 8961 (explaining that the policy represented a response to a
citizen petition filed by an association of device manufacturers that had objected
to the FDA’s mandatory application of nonbinding guidelines); id. at 8963 (dis-
cussing comments alleging past misuses of guidance documents by agency em-
ployees); see also United States v. Bioclinical Sys., Inc., 666 F. Supp. 82, 83–84
(D. Md. 1987) (rejecting the FDA’s effort to require that device manufacturers
adhere to a sterility guideline that had not emerged from notice-and-comment
rulemaking).
38. See Food and Drug Administration Modernization Act (FDAMA), Pub. L. No. 105-
115, § 405 (FDCA § 701(h)(5)), 111 Stat. 2296, 2369 (1997) (codified at 21 U.S.C.
§ 371(h)(5) (2012)); see also S. REP. NO. 105-43, at 26 (1997) (explaining this pro-
vision).  Fifteen years later, Congress made a minor amendment to this provision,
adding that, “[w]ith respect to devices, if a notice to industry guidance letter, a
notice to industry advisory letter, or any similar notice sets forth initial interpre-
tations of a regulation or policy or sets forth changes in interpretation or policy,
such notice shall be treated as a guidance document for purposes of this subpara-
graph.”  Food and Drug Administration Safety and Innovation Act, Pub. L. No.
112-144, § 619(2), 126 Stat. 993, 1064 (2012) (codified at 21 U.S.C.
§ 371(h)(1)(C)(ii) (2012)).
39. See Lewis, supra note 31, at 537 (“[B]y enshrining the GGPs in the FDAMA, Con-
gress has signaled that it expects and desires FDA to make policy through gui-
dance, provided that FDA follows specified procedures.”).  In an otherwise
excellent general overview of federal agencies’ freedom to select among rulemak-
ing, adjudication, prosecution, and guidance (though seemingly oblivious to the
use of threats and other means of exerting informal leverage that I discuss in
Part III), the distinctiveness of the FDA’s development and use of guidance docu-
ments gets essentially no attention. See M. Elizabeth Magill, Agency Choice of
Policymaking Form, 71 U. CHI. L. REV. 1383, 1411 n.96 (2004) (suggesting incor-
rectly that the FDA’s GGPs lack any statutory foundation); id. at 1445 (“Gui-
dance is relatively cheap to produce; it does not require the [FDA] to present its
view to the public for comment or to a court for evaluation.”); cf. id. at 1392 &
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of guidance documents,40 though it directed the agency to “ensure that
employees of the [FDA] do not deviate from such guidances without
appropriate justification and supervisory concurrence.”41  The amend-
ment also sought to ensure that the public have some opportunity to
participate and get reasonable access to them.42  Congress required
that the FDA solicit comments before finalizing major guidance,43
while the agency could wait to solicit public feedback on minor gui-
dance until after the fact.44  The amendment made no provision for
judicial review, demanding only that the agency provide “an effective
appeals mechanism” to address any complaints of noncompliance with
these procedural requirements.45
Less than three months after the deadline imposed by Congress,
the FDA promulgated its final GGPs rule.46  In addition to reiterating
n.20 (explaining that, “in contrast to the other policymaking forms examined
here, guidance documents permit the agency to develop policy relatively cheaply,”
adding that “an agency is not required to present its view to an administrative
tribunal or court, and the agency does not have to solicit or respond to public
comment,” while noting with no elaboration that the FDA “appears to be the most
formalized”); Rakoff, supra note 31, at 170 (“[T]he creation by the FDA of a whole
organized system of rules contained in guidance documents can be seen either as
an example of thoughtful and balanced institutional creativity, or as a brazen
attempt to subvert the APA as construed by the courts.”).
40. See 21 U.S.C. § 371(h)(1)(A) (2012) (“Such documents shall not create or confer
any rights for or on any person, although they present the views of the Secretary
on matters under the jurisdiction of the [FDA].”).
41. Id. § 371(h)(1)(B) (adding that the agency “shall provide training to employees in
how to develop and use guidance documents and shall monitor the development
and issuance of such documents”); see also id. § 371(h)(2) (“In developing gui-
dance documents, the Secretary shall ensure uniform nomenclature for such doc-
uments and uniform internal procedures for approval of such documents.  The
Secretary shall ensure that guidance documents and revisions of such documents
are properly dated and indicate the nonbinding nature of the documents.”).
42. See id. § 371(h)(1)(A) (“The Secretary shall develop guidance documents with
public participation and ensure that information identifying the existence of such
documents and the documents themselves are made available to the public both
in written form and, as feasible, through electronic means.”); id. § 371(h)(3) (“All
such documents shall be made available to the public.”).
43. See id. § 371(h)(1)(C)(i) (“For guidance documents that set forth initial interpre-
tations of a statute or regulation, changes in interpretation or policy that are of
more than a minor nature, complex scientific issues, or highly controversial is-
sues, the Secretary shall ensure public participation prior to implementation of
guidance documents . . . .”).  If, however, the agency “determines that such prior
public participation is not feasible or appropriate,” then it “shall provide for pub-
lic comment upon implementation and take such comment into account.” Id.
44. See id. § 371(h)(1)(D) (“For guidance documents that set forth existing practices
or minor changes in policy, the Secretary shall provide for public comment upon
implementation.”).
45. See id. § 371(h)(4); see also Lewis, supra note 31, at 539, 542 (discussing the in-
ability to seek judicial review); supra note 10 (same).
46. See Final Rule, Administrative Practices and Procedures; Good Guidance Prac-
tices, 65 Fed. Reg. 56,477 (Sept. 19, 2000) (codified at 21 C.F.R. § 10.115 (2014)).
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their nonbinding nature,47 the agency committed itself to using gui-
dance documents rather than other even less formal mechanisms for
announcing policy.48  The agency differentiated between “Level 1” and
“Level 2” guidance documents,49 defining the former category as those
that “(i) Set forth initial interpretations of statutory or regulatory re-
quirements; (ii) Set forth changes in interpretation or policy that are
of more than a minor nature; (iii) Include complex scientific issues; or
(iv) Cover highly controversial issues.”50  Arguably, this definition de-
scribes subjects that the FDA in the past would have handled through
notice-and-comment rulemaking, while only those less consequential
matters viewed as appropriate for Level 2 guidance would have
avoided APA requirements as interpretive rules or general statements
of policy (or nowadays perhaps as candidates for direct final
rulemaking).
Under the GGPs rule, Level 1 guidance documents must undergo a
truncated notice-and-comment procedure,51 while Level 2 guidance
47. See 21 C.F.R. § 10.115(d)(1) (2014) (“Guidance documents do not establish legally
enforceable rights or responsibilities.  They do not legally bind the public or
FDA.”); see also id. § 10.115(d)(2) (“You may choose to use an approach other than
the one set forth in a guidance document. . . .  FDA is willing to discuss an alter-
native approach with you to ensure that it complies with the relevant statutes
and regulations.”); id. § 10.115(d)(3) (“Although guidance documents do not le-
gally bind FDA, they represent the agency’s current thinking.  Therefore, FDA
employees may depart from guidance documents only with appropriate justifica-
tion and supervisory concurrence.”); id. § 10.115(i)(1)(iv) (providing that guidance
must “[p]rominently display a statement of the document’s nonbinding effect”);
id. § 10.115(i)(2) (“Guidance documents must not include mandatory language
such as ‘shall,’ ‘must,’ ‘required,’ or ‘requirement,’ unless FDA is using these
words to describe a statutory or regulatory requirement.”).
48. See id. § 10.115(e) (“The agency may not use documents or other means of com-
munication that are excluded from the definition of guidance document to infor-
mally communicate new or different regulatory expectations to a broad public
audience for the first time.  These GGPs must be followed whenever regulatory
expectations that are not readily apparent from the statute or regulations are
first communicated to a broad public audience.”); see also id. § 10.115(b)(3) (“Gui-
dance documents do not include: Documents relating to internal FDA procedures,
agency reports, general information documents provided to consumers or health
professionals, speeches, journal articles and editorials, media interviews, press
materials, warning letters, memoranda of understanding, or other communica-
tions directed to individual persons or firms.”); id. § 10.115(b)(2) (“Guidance docu-
ments include, but are not limited to, documents that relate to: The design,
production, labeling, promotion, manufacturing, and testing of regulated prod-
ucts; the processing, content, and evaluation or approval of submissions; and in-
spection and enforcement policies.”).
49. Id. § 10.115(c); see also id. § 10.115(c)(2) (adding that “Level 2 guidance docu-
ments include all guidance documents that are not classified as Level 1”).
50. Id. § 10.115(c)(1).
51. See id. § 10.115(g)(1); see also id. § 10.115(g)(2)–(3) (explaining that, when pre-
issuance comment is deemed “not feasible or appropriate” for Level 1 guidance
documents, the agency will invite post-publication comments and consider revis-
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documents only provide an opportunity for post-publication com-
ment.52  The agency promised to make guidance documents available
in hard copy and electronic form,53 and members of the public can, “at
any time, suggest that FDA revise or withdraw an already existing
guidance document.”54  The FDA called upon its various units to en-
sure compliance with GGPs,55 and persons who believe that an em-
ployee has failed to follow these procedures may appeal the issue up
the internal chain of command and, if necessary, to the agency’s
ombudsman.56
Thus, the FDA’s GGPs contemplate a “lite” form of informal
rulemaking, at least for Level 1 guidance documents.57  In some re-
spects, the procedures parallel those associated with notice-and-com-
ing the guidance); id. § 10.115(g)(5) (adding that post-publication comments are
always welcome).
52. See id. § 10.115(g)(4); see also Lewis, supra note 31, at 543 (“The GGPs therefore
provide the public a sufficient forum to voice their concerns regarding politically
salient issues, while granting the agency the necessary flexibility to inexpen-
sively formulate policies on important topics that are either (1) too technical,
complex and esoteric for the general public to understand and comment on, or (2)
too mundane to generate much outcry.”).
53. See 21 C.F.R. § 10.115(m).  Announcements of the availability of Level 1 guidance
documents also would appear in the Federal Register, see id. § 10.115(g)(1)(ii)(A),
(g)(1)(iv)(B), (g)(3)(i)(A), while Level 2 guidance documents simply appear on the
agency’s website, see id. § 10.115(g)(4)(i)(A), though they also would get included
in the comprehensive lists of guidance documents periodically published in the
Federal Register, see id. § 10.115(n)(2).  For more on APA requirements for the
publication of nonlegislative rules, see supra notes 6 & 8.
54. 21 C.F.R. § 10.115(f)(4); see also id. § 10.115(f)(2)–(3) (inviting suggestions for
guidance to develop); id. § 10.115(k)(1) (“The agency will periodically review ex-
isting guidance documents to determine whether they need to be changed or
withdrawn.”); id. § 10.115(k)(2) (“When significant changes are made to the stat-
ute or regulations, the agency will review and, if appropriate, revise guidance
documents relating to that changed statute or regulation.”).
55. See id. § 10.115(l)(2) (“FDA centers and offices will monitor the development and
issuance of guidance documents to ensure that GGPs are being followed.”); see
also id. § 10.115(j) (“Each center and office must have written procedures for the
approval of guidance documents.  Those procedures must ensure that issuance of
all documents is approved by appropriate senior FDA officials.”); id. § 10.115(l)(1)
(“All current and new FDA employees involved in the development, issuance, or
application of guidance documents will be trained regarding the agency’s
GGPs.”).
56. See id. § 10.115(o).  For a discussion of a similar internal appeal mechanism, see
Karen M. Becker et al., Scientific Dispute Resolution: First Use of Provision 404 of
the Food and Drug Administration Modernization Act of 1997, 58 FOOD & DRUG
L.J. 211, 212–13 (2003).
57. See Lewis, supra note 31, at 536 (“The GGPs and the FDAMA established unprec-
edented opportunities for public participation in the guidance-making and gui-
dance-revising process, and imposed procedural requirements akin to notice-and-
comment rulemaking, albeit slightly more lenient.”); id. at 544 (“[T]he GGPs sub-
ject FDA proposals to a probing review process that approximates the rigor of
notice-and-comment rulemaking and provides opportunities for public participa-
tion.”); cf. Hunnicutt, supra note 33, at 180 (“[I]f the agency is going to accept
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ment rulemaking.58  In other respects, however, the procedures
demand far less of the FDA, especially the absence of any need to offer
detailed responses to public comments.59  Then again, the APA’s re-
quirement for a “concise general statement of the [rule’s] basis and
purpose”60 plainly never meant to impose such a requirement for leg-
islative rules though courts later so interpreted it.61  In short, Level 1
guidance documents produced consistent with the GGPs—coupled
with the absence of routine opportunities for “pre-enforcement” judi-
cial review (technically, of course, a misnomer in this context) or close
scrutiny by the other two branches of government—may reflect some-
thing of a throwback to informal rulemaking as originally conceived.62
Congress instructed the FDA “periodically” to publish a list of gui-
dance documents in the Federal Register,63 and the GGPs rule com-
commentary prior to implementing a [Level 1 guidance], why not simply employ
informal notice-and-comment rulemaking as defined in the APA?”).
58. See, e.g., 21 C.F.R. § 10.115(g)(1)(v) (noting that the agency may decide to issue a
revised draft for another round of comments); see also id. § 10.115(g)(1)(iii)(B)
(explaining that it may invite advisory committee review).
59. See id. § 10.115(g)(1)(iv)(A) (providing only that it will “[r]eview any comments
received and prepare the final version of the guidance document that incorpo-
rates suggested changes, when appropriate”); see also id. § 10.115(h)(3) (explain-
ing that comments submitted to the Division of Dockets Management remain
available for public inspection); Lewis, supra note 31, at 522 (“Level 1 guidance
does not require the agency to respond to significant comments it receives . . . .
This frees FDA from one of the major procedural burdens associated with notice-
and-comment rulemaking.”). But cf. Johnson, supra note 7, at 541 n.322 (“[T]he
FDA has committed to full notice-and-comment procedures for ‘Level 1 guidance
documents.’ . . .  For guidance documents that are not Level 1, the FDA posts the
guidance documents on the Internet and gives the public an opportunity to com-
ment, but the FDA does not need to reply to those comments.”).
60. 5 U.S.C. § 553(c) (2012).
61. See Lars Noah, Divining Regulatory Intent: The Place for a “Legislative History”
of Agency Rules, 51 HASTINGS L.J. 255, 308–10 (2000); Rakoff, supra note 31, at
163–65; Peter L. Strauss, From Expertise to Politics: The Transformation of
American Rulemaking, 31 WAKE FOREST L. REV. 745, 753, 757, 760 (1996).
62. See Rakoff, supra note 31, at 169 (“It would not be far-fetched to rephrase these
[GGPs for Level 1 guidance documents] by saying that the FDA now proposes to
issue its important regulations mostly in accordance with the notice-and-com-
ment rulemaking procedure set forth in the APA, as it was understood before
1970.  The only difference is that, at least in the agency’s view, the entire matter
will be beyond the purview of the courts.”); see also Jessica Mantel, Procedural
Safeguards for Agency Guidance: A Source of Legitimacy for the Administrative
State, 61 ADMIN. L. REV. 343, 398–405 (2009) (favoring a requirement that both
major and minor guidance allow for pre-adoption public comment and include a
concise explanatory statement to accompany the final guidance but without any
need to respond to particular comments); id. at 403–04 (“[M]y proposed limited
notice-and-comment process parallels the notice-and-comment process followed
by agencies from enactment of the APA through the 1960s.”).
63. See 21 U.S.C. § 371(h)(3) (2012); see also id. § 371(h)(2) (“The Secretary shall pe-
riodically review all guidance documents and, where appropriate, revise such
documents.”).
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mitted to doing so annually.64  In practice, however, these lists have
appeared somewhat irregularly.65  The latest version reveals almost
two thousand guidance documents, in both draft and final form,66 and
in recent years the FDA has produced more than a hundred new ones
annually,67 easily outpacing the frequency of notice-and-comment
rulemaking.68
It did not take long for complaints to surface about ossification of
the FDA’s guidance-making process.69  Perhaps that explains why
64. See 21 C.F.R. § 10.115(n)(2); see also id. § 10.115(f)(5) (“Once a year, FDA will
publish, both in the FEDERAL REGISTER and on the Internet, a list of possible top-
ics for future guidance document development or revision during the next year.”);
Notice, Annual Guidance Agenda, 75 Fed. Reg. 76,011 (Dec. 7, 2010).
65. See Notice, Comprehensive List of Current Guidance Documents at the Food and
Drug Administration, 63 Fed. Reg. 9795 (Feb. 26, 1998); Notice, Annual Compre-
hensive List of Guidance Documents at the Food and Drug Administration, 64
Fed. Reg. 31,228 (June 10, 1999); Notice, Annual Comprehensive List of Gui-
dance Documents at the Food and Drug Administration, 65 Fed. Reg. 45,428
(July 21, 2000); Notice, Annual Comprehensive List of Guidance Documents at
the Food and Drug Administration, 66 Fed. Reg. 53,836 (Oct. 24, 2001); Notice,
Annual Comprehensive List of Guidance Documents at the Food and Drug Ad-
ministration, 70 Fed. Reg. 824 (Jan. 5, 2005); Notice, Annual Comprehensive List
of Guidance Documents at the Food and Drug Administration, 71 Fed. Reg.
15,422 (Mar. 28, 2006).
66. See Notice, Comprehensive List of Guidance Documents at the Food and Drug
Administration, 75 Fed. Reg. 48,180 (Aug. 9, 2010).  Current lists (divided by sub-
ject matter) also appear on the agency’s website, see REGULATORY INFORMATION,
Guidances, http://www.fda.gov/RegulatoryInformation/Guidances/default.htm
(last visited July 5, 2013), archived at http://perma.unl.edu/5NTR-4FAY, which
should reflect new guidance documents within 30 days of issuance, see 21 C.F.R.
§ 10.115(n)(1).
67. See Notice of Availability, Food and Drug Administration Report on Good Gui-
dance Practices: Improving Efficiency and Transparency, 76 Fed. Reg. 82,311,
82,312 (Dec. 30, 2011) (“In fiscal year (FY) 2009, the Agency issued approxi-
mately 124 guidance documents.  Since that time, its issuance of guidance docu-
ments has been trending upward, with the Agency issuing approximately 133
guidance documents in FY 2010 and approximately 144 guidance documents in
FY 2011.”); see also Lewis, supra note 31, at 549–50 fig.5 (enumerating the an-
nual production of guidance at the FDA over the last quarter of a century); id. at
537 (“[S]tatistics suggest its annual output of guidance has increased regularly
since the formulation of the GGPs.”).
68. See Erica Seiguer & John J. Smith, Perception and Process at the Food and Drug
Administration: Obligations and Trade-Offs in Rules and Guidances, 60 FOOD &
DRUG L.J. 17, 25–26 (2005) (finding more than twice as many Level 1 guidance
documents as regulations issued by the FDA between 2001 and 2003).
69. See id. at 24 (“[T]he development of guidances has come to resemble rulemaking
in terms of the extent of clearance and time required to develop and implement
them.”); id. at 27 (“Several individuals involved in both rulemaking and guidance
development and implementation voiced concern about the increased layers of
review . . . [and] worried that the additional scrutiny of guidances may detract
from their utility as they become less flexible and responsive. . . .  For some, this
is a by-product of the formalization of the guidancemaking process in the
GGPs . . . .”); id. at 32 (“Some agency officials and stakeholders suggest that in-
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Level 1 guidance often remain in draft form,70 which makes the proce-
dures for their issuance (as drafts) essentially the same as those used
for Level 2 guidance.  For instance, the FDA recently has attracted
criticism for its failure to finalize a draft guidance on mobile health
applications issued in 2011.71  In any case, and in spite of their explic-
itly “nonbinding” character, draft or final guidance still often operate
creasing formality in the creation of guidances and more extensive oversight may
hinder the speed and flexibility of their development.  To the extent that
rulemaking and guidance development are approximating each other in terms of
time and resources required, some of the advantages of guidances may be di-
luted.”); see also Michael Asimow, Guidance Documents in the States: Toward a
Safe Harbor, 54 ADMIN. L. REV. 631, 647 (2002) (describing a similar trajectory in
California); id. at 632 (“[A]n agency should be permitted to adopt guidance docu-
ments without any pre-adoption procedures.”); Peter L. Strauss, The Rulemaking
Continuum, 41 DUKE L.J. 1463, 1481 (1992) (“[I]t would be unreasonable to ex-
pect that any significant portion of today’s publication rules would appear if no-
tice-and-comment rulemaking were required for their adoption.”).
70. See Seiguer & Smith, supra note 68, at 31 (“Another aspect of the concern over
timeliness was voiced concerning the existence and persistence of draft guid-
ances, often for years after an NOA [notice of availability] is published in the
Federal Register.  These documents, although in draft form and not issued as fi-
nal documents, come to represent final guidances.”); see also Noah, supra note 34,
at 127 & n.56 (discussing this tendency prior to adoption of the GGPs policy).
This may happen when the FDA gets inundated with comments, as happened
after it issued a draft (and not yet finalized) guidance document on unorthodox
treatments more than six years ago. See Notice of Availability, Draft Guidance
for Industry on Complementary and Alternative Medicine Products and Their
Regulation by the Food and Drug Administration, 72 Fed. Reg. 29,337, 29,338
(May 25, 2007) (noting the receipt of “a large volume of comments”); see also No-
tice of Availability, Draft Guidance for Industry: Voluntary Labeling Indicating
Whether Foods Have or Have Not Been Developed Using Bioengineering, 66 Fed.
Reg. 4839 (Jan. 18, 2001) (noting the receipt of more than 50,000 written com-
ments).  Conversely, the agency may invoke the power to skip the draft (and com-
ment) stage on questionable grounds. See, e.g., Notice of Availability, Compliance
Policy Guide: Compounding of Drugs for Use in Animals, 68 Fed. Reg. 134 (July
14, 2003) (explaining the failure to first solicit public comment on this Level 1
guidance document because the agency needed to revise its policy in response to a
Supreme Court decision issued more than a year earlier).  Recently, one FDA
Center recognized that it had dozens of drafts that were more than three years
old. See Notice, Retrospective Review of Draft Guidance Documents Issued
Before 2010, 78 Fed. Reg. 48,175 (Aug. 7, 2013) (promising to either withdraw or
finalize them).
71. See Hayley Tsukayama, Lawmakers Press for Medical-App Rules, WASH. POST,
Mar. 13, 2013, at A14; see also GOP Senators Criticize FDA Delays in Finalizing
Draft Guidances, DRUG INDUS. DAILY, May 9, 2014, available at 2014 WLNR
12430760 (discussing a letter sent by members of an oversight committee to the
Commissioner objecting that “draft guidances are becoming default FDA policy”).
Previously, a pair of Senators had sponsored an amendment to a pending bill
designed to delay finalization of this draft. See Dina ElBoghdady, Feeling Sick?
There’s an App for That, WASH. POST, June 24, 2012, at G1.  The agency eventu-
ally did issue a final version. See Notice of Availability, Mobile Medical Applica-
tions; Guidance for Industry and Food and Drug Administration Staff, 78 Fed.
Reg. 59,038 (Sept. 25, 2013); Thomas M. Burton, FDA Updates Its Guidance on
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as de facto requirements.72  In recognition of this fact, some commen-
tators have recommended—though without focusing on the FDA spe-
cifically—that courts entertain pre-enforcement challenges,73 which
no doubt would serve to bring guidance-making full circle back to leg-
islative rulemaking with all of the difficulties that process has en-
tailed for agencies.
2. Congressional Demands for FDA Guidance
Congress did not simply endorse the FDA’s GGPs in 1997; in that
same legislation, it also called for the issuance of guidance related to a
few specific subjects.74  Increasingly over the last decade, Congress
Mobile-Software Apps, WALL ST. J., Sept. 24, 2013, at B4 (reporting that it had
received 130 comments on the draft, which prompted substantial changes).
72. See, e.g., Hood v. Wholesoy & Co., No. 12-cv-5550-YGR, 2013 WL 3553979, at
*2–3 (N.D. Cal. July 12, 2013) (noting a pair of 2012 FDA warning letters that
referenced a 2009 draft guidance on use of the term “evaporated cane juice” (ECJ)
on food labels); id. at *5 (“[T]he Draft ECJ Guidance on which Plaintiff [in this
consumer fraud action] relies says expressly that it is not a ‘legally enforceable’
standard, but only a suggestion.  Given that statement, it is unclear why FDA
subsequently has issued two warning letters citing that guidance.  At a mini-
mum, this indicates to the Court that the FDA’s position is not settled.”); BBK
Tobacco & Foods, LLP v. FDA, 672 F. Supp. 2d 969, 974–76 (D. Ariz. 2009); see
also Seiguer & Smith, supra note 68, at 29 (“While the enforcement implications
differ for rules and guidances, in practice most of those interviewed said that
industry treats guidances no differently than rules.”); infra Part III (elaborating
on some of the reasons for this).
73. See Mark Seidenfeld, Substituting Substantive for Procedural Review of Gui-
dance Documents, 90 TEX. L. REV. 331, 373–94 & n.265 (2011) (favoring substan-
tive review of these “pragmatically binding” documents even while recognizing
the risk of ossifying the process); see also Robert A. Anthony & David A.
Codevilla, Pro-Ossification: A Harder Look at Agency Policy Statements, 31 WAKE
FOREST L. REV. 667, 676–92 (1996) (urging more stringent judicial review under
the arbitrary and capricious standard); id. at 669 (conceding that this might os-
sify nonlegislative rulemaking); id. at 672–73 n.21, 677 n.35 (discussing, without
suggesting changes to, ripeness doctrine).
74. See Food and Drug Administration Modernization Act, Pub. L. No. 105-115,
§ 112(b), 111 Stat. 2296, 2310 (1997) (requiring that, within one year of enact-
ment, the agency issue guidance describing the policies and procedures for “fast
track” drug approvals); id. §§ 119(a) (FDCA § 505(b)(4)(A)), 119(b)(1)(B) (FDCA
§ 505(j)(3)(A)), 111 Stat. at 2316–17 (codified at 21 U.S.C. §§ 355(b)&(j) (2012))
(calling for the issuance of guidance for reviewers of biologic product applica-
tions); id. § 206(c)(2) (FDCA § 513(i)(1)(F)), 111 Stat. at 2340 (codified at 21
U.S.C. § 360c(i)(1)(F) (2012)) (requiring that, within 270 days of enactment, the
agency issue guidance relating to intended use determinations for purposes of
making judgments about the substantial equivalence of medical devices); id.
§ 403(b), 111 Stat. at 2367 (requiring that, within 180 days of enactment, the
agency issue guidance to industry to clarify the requirements for applications
seeking supplemental product approvals); see also id. § 116(a) (FDCA
§ 506A(c)(2)), 111 Stat. at 2314 (codified at 21 U.S.C. § 356a(c)(2) (2012)) (al-
lowing the agency to issue either “regulation or guidance” to implement new re-
quirements governing major manufacturing changes for approved drugs).
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has directed the FDA to publish guidance documents on a number of
other subjects that it wants the agency to address.75  In 2006, for in-
stance, it gave the agency approximately nine months to issue gui-
dance on “minimum data elements that should be included in a
75. See, e.g., Drug Quality and Security Act, Pub. L. No. 113-54, § 202 (FDCA
§ 582(a)(2)), 127 Stat. 587, 605–06 (2013) (to be codified at 21 U.S.C. § 360eee-
1(a)(2)) (requiring, within one year of enactment, draft guidance to establish
standards for the exchange of drug transaction information but issued only after
first providing a 60 day public comment period); id. § 202 (FDCA § 582(a)(3),
(a)(5)(A)), 127 Stat. at 606–07 (to be codified at 21 U.S.C. § 360eee-1(a)(3),
(a)(5)(A)) (requiring, within two years of enactment, guidance governing waivers,
exceptions, and exemptions from these standards); id. § 203 (FDCA § 582(h)), 127
Stat. at 626–28 (to be codified at 21 U.S.C. § 360eee-1(h)) (requiring several types
of guidance related to drug tracing requirements, specifying procedures for their
issuance and revision that seem somewhat more demanding than GGPs for Level
1 guidance, and providing that these nonbinding pronouncements not take effect
for one year); Pandemic and All-Hazards Preparedness Reauthorization Act of
2013, Pub. L. No. 113-5, § 304(3), 127 Stat. 161, 187 (to be codified at 21 U.S.C.
§ 360bbb-4(c)) (requiring that, within one year of enactment, the agency issue
final guidance regarding acceptable animal models for the licensing of counter-
measures); Food and Drug Administration Safety and Innovation Act, Pub. L. No.
112-144, § 806, 126 Stat. 993, 1082 (2012) (requiring, by Dec. 31, 2014, final Level
1 guidance about “pathogen-focused antibacterial drug development”); id.
§ 901(c), 126 Stat. at 1085–86 (requiring that, within two years of enactment, the
FDA issue a final Level 1 guidance document on accelerated drug approval); id.
§ 1121, 126 Stat. at 1112 (requiring, within two years of enactment, guidance on
Internet promotion); FDA Food Safety Modernization Act, Pub. L. No. 111-353,
§ 113(b), 124 Stat. 3885, 3921 (2011) (calling for the issuance of guidance within
180 days of enactment to clarify the meaning of and requirements for new dietary
supplement ingredients); Family Smoking Prevention and Tobacco Control Act,
§ 101(b) (FDCA § 911(l)(1)), 123 Stat. 1776, 1818 (2009) (codified at 21 U.S.C.
§ 387k(l)(1) (2012)) (“Not later than 2 years after the date of enactment . . . , the
Secretary shall issue regulations or guidance (or any combination thereof) on the
scientific evidence required for assessment and ongoing review of modified risk
tobacco products.”); id. § 101(q)(1), 123 Stat. at 1838 (calling for guidance about
enforcement against retailers); id. § 101(q)(3), 123 Stat. at 1840 (providing that
certain amendments related to penalties only become effective upon the issuance
of such guidance); Food and Drug Administration Amendments Act of 2007, Pub.
L. No. 110-85, § 303(c), 121 Stat. 823, 862–63 (requiring that, within 180 days of
enactment, the agency issue guidance to clarify the humanitarian device exemp-
tion); id. § 701(a) (FDCA § 712(f)), 121 Stat. at 903 (codified at 21 U.S.C. § 379d-
1(f) (2012)) (“Not less than once every 5 years, the Secretary shall review gui-
dance of the [FDA] regarding conflict of interest waiver determinations with re-
spect to advisory committees and update such guidance as necessary.”); id. § 911
(FDCA § 511), 121 Stat. at 951 (codified at 21 U.S.C. § 360a (2012)) (requiring
that, within one year of enactment, the agency issue (and, within five years, re-
view and update) guidance for the conduct of clinical trials with respect to antibi-
otic drugs); id. § 1005(f), 121 Stat. at 969 (requiring that, within 270 days of
enactment, the agency issue guidance to the industry about submitting reports to
a new electronic portal identifying food safety problems); Medical Device User
Fee and Modernization Act of 2002, Pub. L. No. 107-250, § 213, 116 Stat 1588,
1614–15 (requiring that, within 270 days of enactment, the agency issue gui-
dance regarding pediatric devices).
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serious adverse event report” for nonprescription drugs and dietary
supplements.76  In contrast, when decades earlier it gave the FDA
power to require such reporting for prescription drugs and medical de-
vices, Congress required that the agency use notice-and-comment
rulemaking to spell out such details.77  In 2010, when Congress cre-
ated an approval pathway for generic biologics (so-called “biosimi-
lars”), it directed the agency to produce implementing guidance,
though only after first soliciting public comment—in effect, calling for
the issuance of Level 1 guidance.78  In contrast, when it codified an
approval pathway for generic versions of conventional pharmaceutical
products a quarter of a century earlier, Congress demanded that the
FDA engage in notice-and-comment rulemaking to craft implementing
regulations.79
76. See Dietary Supplement and Nonprescription Drug Consumer Protection Act,
Pub. L. No. 109-462, §§ 2(e)(3), 3(d)(3), 120 Stat. 3469, 3472, 3475 (2006).
77. See Drug Amendments of 1962, Pub. L. No. 87-781, § 103(a) (FDCA § 505(j)(1)),
76 Stat. 780, 782–83 (codified as amended at 21 U.S.C. § 355(k)(1) (2012)) (calling
for general regulations or specific orders to define what reports manufacturers of
approved drugs must submit); Medical Device Amendments of 1976, Pub. L. No.
94-295, § 2 (FDCA § 519(a)), 90 Stat. 539, 564–65 (codified as amended at 21
U.S.C. § 360i(a) (2012)) (calling for regulations to define what reports device
manufacturers, importers, and distributors must submit); cf. Safe Medical De-
vices Act of 1990, Pub. L. No. 101-629, § 5(a)(2) (FDCA § 513(a)(1)(B)), 104 Stat.
4511, 4517–18 (codified at 21 U.S.C. § 360c(a)(1)(B) (2012)) (directing the FDA to
develop and disseminate guidelines for Class II medical devices).  Of course, the
FDA uses guidance documents to elaborate on its regulations implementing these
statutory provisions. See, e.g., Notice of Availability, Draft Guidance: Medical
Device Reporting for Manufacturers, 78 Fed. Reg. 41,069 (July 9, 2013).
78. See Biologics Price Competition and Innovation Act, Pub. L. No. 111-148,
§ 7002(a)(2) (PHSA § 351(k)(8)), 124 Stat. 119, 808 (2010) (codified at 42 U.S.C.
§ 262(k)(8) (2012)) (cross-referencing 21 U.S.C. § 371(h)); see also Notice of Public
Hearing, Draft Guidances Relating to the Development of Biosimilar Products, 77
Fed. Reg. 12,853, 12,854 (Mar. 2, 2012) (requesting comments on three draft gui-
dance documents that it had issued a few weeks earlier); Katie Thomas, Generic
Drug Makers See a Drought Ahead, N.Y. TIMES, Dec. 4, 2012, at B1 (reporting
that “the F.D.A. was not expected to issue guidelines for approving biosimilars
anytime soon”).  This exercise will provoke serious controversy, and the choices
that the FDA ultimately makes will have tremendous financial consequences.
79. See Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L.
No. 98-417, § 105(a), 98 Stat. 1585, 1597 (imposing a one year deadline for doing
so); see also 21 C.F.R. pts. 314(C), 320 (2014) (implementing rules).  Of course, the
FDA has further elaborated on these regulations with guidance. See, e.g., Notice
of Availability, Draft Guidance for Industry on Abbreviated New Drug Applica-
tions: Stability Testing of Drug Substances and Products, 77 Fed. Reg. 58,999
(Sept. 25, 2012); Notice of Availability, Guidance for Industry on Abbreviated
New Drug Applications: Impurities in Drug Substances, 74 Fed. Reg. 34,359
(July 15, 2009); Notice of Availability, Draft Guidance for Industry on the Sub-
mission of Summary Bioequivalence Data for Abbreviated New Drug Applica-
tions, 74 Fed. Reg. 17,872 (Apr. 17, 2009); see also In re Flonase Antitrust Litig.,
795 F. Supp. 2d 300, 304–05, 312 (E.D. Pa. 2011) (explaining the agency’s ten-
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The sweeping food safety amendments enacted in 2011 are littered
with congressional demands for the issuance of guidance.  A central
provision of this legislation called for the use of an approach based on
a strategy previously known as hazard analysis and critical control
points (HACCP), and it included a requirement that the FDA issue
implementing regulations within eighteen months,80 coupled with
several requirements for the issuance of related guidance docu-
ments.81  The very next section of the new law called on the agency to
issue (and periodically revise as necessary) “performance standards”
related to specific food contaminants either as guidance documents or
as regulations,82 a peculiar concession about their interchangeability
that had appeared occasionally in earlier legislation.83 Congress also
dency to rely on draft guidance documents to outline its expectations for the test-
ing of generic drugs).
80. See FDA Food Safety Modernization Act, Pub. L. No. 111-353, § 103(a) (FDCA
§ 418(n)), 124 Stat. 3885, 3895 (2011) (codified at 21 U.S.C. § 350g(n) (2012)).
Congress separately included details about the intended scope of this rulemaking
process. See id. § 103(c), 124 Stat. at 3896–98.
81. See id. § 103(b), 124 Stat. at 3896 (calling for guidance related to this rulemaking
though without specifying any particular time frame); id. § 103(d), 124 Stat. at
3898 (calling for the issuance of a compliance policy guide for small entities
within 180 days of promulgation of implementing regulations); id. § 103(h), 124
Stat. at 3898 (calling for updates of existing guidance on HACCP for fish within
180 days of enactment).  A similar pattern—namely, required rulemaking plus
the issuance of affiliated guidance—appears in several other new provisions: (1)
standards for produce safety, see id. § 105(a) (FDCA § 419(a)–(c)), 124 Stat. at
3899–902 (codified at 21 U.S.C. § 350h(a)–(c) (2012)) (rulemaking within two
years); id. (FDCA § 419(e)), 124 Stat. at 3902–03 (codified at 21 U.S.C. § 350h(e))
(guidance within one year); id. § 105(b), 124 Stat. at 3904 (calling for the issuance
of a compliance policy guide for small entities within 180 days of promulgation of
implementing regulations); (2) protection against terrorist attacks on the food
supply, see id. § 106(a) (FDCA § 420(b)), 124 Stat. at 3905 (codified at 21 U.S.C.
§ 350i(b) (2012)) (rulemaking within eighteen months); id. § 106(b), 124 Stat. at
3906 (guidance within one year); id. § 106(c) (calling for periodic review of both
the implementing regulations and guidance documents); and (3) foreign supplier
verification, see id. § 301(a) (FDCA § 805(c)), 124 Stat. at 3953 (codified at 21
U.S.C. § 384a(c) (2012)) (rulemaking within one year); id. (FDCA § 805(b)) (codi-
fied at 21 U.S.C. § 384a(b)) (guidance within one year); see also id. § 302 (FDCA
§ 806(a)(2)), 124 Stat. at 3955 (codified at 21 U.S.C. § 384b(a)(2) (2012)) (calling
for guidance within eighteen months about participation in a voluntary qualified
importer program).
82. See id. § 104(b), (d), 124 Stat. at 3899; see also Drug Quality and Security Act,
Pub. L. No. 113-54, § 102(a)(2) (FDCA § 503B(b)(5)), 127 Stat. 587, 591 (2013) (to
be codified at 21 U.S.C. § 353b(b)(5)) (formatting requirements for reports of com-
pounded drugs produced by registered outsourcing facilities); id. § 102(a)(2)
(FDCA § 503B(b)(2)(B)), 127 Stat. at 592 (to be codified at 21 U.S.C.
§ 353b(b)(2)(B)) (adverse event reporting by such facilities).
83. See Family Smoking Prevention and Tobacco Control Act, § 101(b) (FDCA
§ 911(l)(1)), 123 Stat. 1776, 1818 (2009) (codified at 21 U.S.C. § 387k(l)(1) (2012));
Food and Drug Administration Modernization Act, Pub. L. No. 105-115, § 116(a)
(FDCA § 506A(c)(2)), 111 Stat. 2296, 2314 (1997) (codified at 21 U.S.C. § 356a
(2012)).
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demanded that the FDA submit certain guidance documents to partic-
ular subcommittees for prior review.84
In short, statutory amendments enacted during the last couple of
decades include more than thirty separate provisions that invite or
require guidance-making by the FDA.  In light of this recent legisla-
tive tendency to call for the issuance of guidance by the agency, which
may reflect an effort by Congress to insulate the FDA’s policymaking
from White House review,85 little doubt remains about the legitimacy
84. See FDA Food Safety Modernization Act, § 114(a), 124 Stat. at 3921 (requiring
that a pair of congressional committees get at least ninety days advance notice of
any FDA guidance document or regulation relating to post harvest processing of
raw oysters); see also Food and Drug Administration Safety and Innovation Act,
Pub. L. No. 112-144, § 1143(a), 126 Stat. 993, 1130 (2012) (requiring that a pair of
congressional committees get at least sixty days advance notice of any FDA gui-
dance document expressing an intent to regulate laboratory-developed tests);
United States v. Franck’s Lab, Inc., 816 F. Supp. 2d 1209, 1229–30, 1252 (M.D.
Fla. 2011) (discussing congressional frustration with the FDA’s failure to revise
its guidance on compounding of veterinary drugs); S. REP. NO. 113-164, at 81
(2014) (“The Committee [on Appropriations] is concerned that the Food and Drug
Administration is not meeting any stakeholders before publicly releasing further
guidance [on pharmacy compounding] for public comment.”); cf. Food and Drug
Administration Modernization Act, Pub. L. No. 105-115, § 121(d), 111 Stat. 2296,
2321–22 (1997) (requiring that, within thirty days of enactment, the agency with-
draw a pair of guidance documents published in 1995 that related to positron
emission tomography (PET) radiopharmaceutical drug products).
85. Cf. Nou, supra note 11, at 1835 (“Congress could dictate specific policymaking
forms that are more likely, as a class, to bypass presidential review; for example,
prohibiting rulemaking would channel policymaking to other forms such as gui-
dance documents.”). See generally McGarity, supra note 3, at 1397 (“[I]nformal
rulemaking has evolved in an environment of intense institutional competition.
Congress and the President have been vying for control over this important poli-
cymaking tool.”); Sidney A. Shapiro, Political Oversight and the Deterioration of
Regulatory Policy, 46 ADMIN. L. REV. 1, 4 (1994) (discussing “the ‘negative-sum’
nature of presidential and legislative competition concerning oversight”).  It also
might serve to reduce the involvement of meddlesome courts, thereby arguably
making the FDA relatively more responsive to Congress—which engages in ad-
mittedly sporadic review but without differentiating between binding and non-
binding rules—than the other two branches of government. Contrary to the
claims of some commentators, see, e.g., Mendelson, supra note 12, at 411, the
Congressional Review Act (CRA), 5 U.S.C. §§ 801–808 (2012), does apply to gui-
dance documents, see id. § 804(3); Strauss, supra note 61, at 769 (“Every action
an agency takes that fits the APA’s definition of ‘rule,’ not only legislative rules
but also the much larger volume of interpretive rules, statements of policy and
other forms of guidance, must be provided to Congress for consideration under
the disapproval procedure.”); see also Morton Rosenberg, CONG. RESEARCH SERV.,
RL30116, CONGRESSIONAL REVIEW OF AGENCY RULEMAKING: AN UPDATE AND AS-
SESSMENT OF THE CONGRESSIONAL REVIEW ACT AFTER A DECADE 25–28 (2008),
archived at http://perma.unl.edu/89ES-QM74 (same, but recognizing that agen-
cies generally have not been sending their nonlegislative rules to Congress);
supra notes 71 & 84 (identifying instances of congressional review of FDA gui-
dance documents, including an order to withdraw a pair related to PET drugs,
110 NEBRASKA LAW REVIEW [Vol. 93:89
of this general development.86  It poses, however, a curious question.
Several commentators have discussed the degree of deference owed by
courts when evaluating agency interpretations of ambiguous statutory
language that appear in guidance documents instead of regulations.87
No one appears to have considered the extent to which an explicit con-
gressional order to issue guidance on a particular matter should factor
into the analysis, but it seems that such a delegation of authority
might justify granting an agency interpretation significant deference
even if the guidance document emerged without the exact procedures
required for binding rules (though Level 1 comes close).88  If granted
significant deference by the courts, however, then nonbinding gui-
dance documents would have an even stronger de facto binding effect
on regulated entities.89
3. Extending GGPs to Other Agencies?
If the shift to guidance struck it as salutary, then it seems at least
mildly curious that Congress did not amend the APA so that the same
procedures would apply to other federal agencies when they use gui-
dance documents.  Partly, of course, it reflected the fact that Congress
had to reauthorize the soon-to-sunset drug user fee legislation in
1997,90 and that happened just as the FDA had begun to structure its
guidance development process.  It also may have reflected a prefer-
which represents twice the number of rules issued by any agency that Congress
has ever overridden using the CRA).
86. Cf. Raso, supra note 13, at 814 & n.144 (pointing out that “Congress occasionally
requires agencies to issue guidance documents,” and noting that critics “often
neglect [to recognize] th[is] fact,” but citing only one largely inapt illustration).
Unlike Mr. Raso, I have tried to document the extent to which this happens at
least with regard to one agency.  I have no idea whether Congress acts similarly
with regard to other agencies, which it has not made subject to GGPs, see infra
note 92, though I have come across one other illustration of this phenomenon
mentioned in the scholarly literature, see The Energy Independence and Security
Act of 2007, Pub. L. No. 110-140, § 433(d), 121 Stat. 1492, 1614 (2007) (cited by
Kalen, supra note 13, at 716 & n.350).
87. See, e.g., Kristin E. Hickman, Unpacking the Force of Law, 66 VAND. L. REV. 465,
484–90, 511–25 (2013); John F. Manning, Nonlegislative Rules, 72 GEO. WASH. L.
REV. 893, 937–44 (2004).
88. Cf. Barnhart v. Walton, 535 U.S. 212, 222 (2002) (enumerating relevant factors);
United States v. Mead Corp., 533 U.S. 218, 229 (2001) (asking whether Congress
gave the agency “the responsibility to implement a particular provision or fill a
particular gap”); Funk, supra note 6, at 1347–48 (explaining that agencies do not
need any specific delegated authority to issue nonlegislative rules).
89. See Randolph J. May, Ruling Without Real Rules—or How to Influence Private
Conduct Without Really Binding, 53 ADMIN. L. REV. 1303, 1308–09 (2001);
Thomas J. Fraser, Note, Interpretive Rules: Can the Amount of Deference Ac-
corded Them Offer Insight into the Procedural Inquiry?, 90 B.U. L. REV. 1303,
1325–26 (2010).
90. See Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, § 105, 106 Stat.
4491, 4498 (codified as amended at 21 U.S.C. §§ 379g–379h (2012)).  In addition,
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ence for experimenting with these hybridized procedures before im-
posing them across the board,91 but, more than fifteen years later,
Congress has shown no real interest in broadening the reach of
GGPs.92
Instead, in 2007, OMB took this additional step by calling on Exec-
utive branch agencies to adopt GGPs loosely modeled on the FDA’s
approach.93  In addition, one week earlier, the White House had is-
sued an Executive Order to clarify, among other things, that these
same agencies (including the FDA) should seek OMB clearance of any
“economically significant” guidance documents.94  The suggestion that
of course, the APA rarely gets amended. See Peter L. Strauss, Changing Times:
The APA at Fifty, 63 U. CHI. L. REV. 1389, 1391–92 (1996).
91. See Rakoff, supra note 31, at 172 (“While a judgment as to the success of the
precise procedures the FDA has chosen to use in establishing its organized sys-
tem of half-formal, half-informal ‘guidance’ must await the test of time, it seems
to me experiments of this sort are well worth pursuing.”).
92. See Mendelson, supra note 12, at 401 & n.25 (explaining that, notwithstanding
various proposals previously introduced in Congress and “extensive oversight in
2000,” FDAMA remains the only statute addressing the development and use of
guidance documents); see also McKee, supra note 10, at 380 (“The FDA is unusual
among federal agencies in that it has codified statutory provisions addressing
guidance documents.”); Hunnicutt, supra note 33, at 185 (“The GGPs, however,
apply to only one agency.  To establish greater efficiency and consistency in the
use of nonlegislative rules throughout the federal government, Congress ought to
revise nonlegislative rules for all agencies.”); id. at 190–91 (elaborating); cf. Wil-
liam Funk, Legislating for Nonlegislative Rules, 56 ADMIN. L. REV. 1023 (2004)
(offering proposed amendments to the APA, but geared toward facilitating sub-
stantive judicial review rather than modeled on the GGPs).  For a recent bill that
would do so, see the Clearing Unnecessary Regulatory Burdens Act, S. 602, 112th
Cong. (2011).
93. See Notice, Final Bulletin for Agency Good Guidance Practices, 72 Fed. Reg.
3432, 3439–40 (Jan. 25, 2007) [hereinafter OMB Bulletin] (covering only “signifi-
cant” guidance documents, and calling for pre-issuance comment opportunity
only for a subset deemed “economically significant,” though agencies would have
to prepare and make available a response to any public comments on the latter);
id. at 3438 (explaining that agencies “must prepare a robust response-to-com-
ments document,” conceding that “these procedures are similar to APA notice-
and-comment requirements”); id. at 3433 (“The provisions of the FDAMA and
FDA’s implementing regulations . . . informed the development of this govern-
ment-wide Bulletin.”); id. at 3434 (explaining differences between its definition of
“significant” guidance documents and the FDA’s “Level 1” category); see also Ste-
phen M. Johnson, Good Guidance, Good Grief!, 72 MO. L. REV. 695, 722–26,
732–33 (2007) (describing and critiquing this initiative); Mendelson, supra note
12, at 447–50 (discussing limitations with OMB’s call for other agencies to adopt
GGPs); Paul R. Noe & John D. Graham, Due Process and Management for Gui-
dance Documents: Good Governance Long Overdue, 25 YALE J. ON REG. 103 (2008)
(providing a brief defense of the OMB Bulletin penned by its authors); Cindy
Skrzycki, Bush Order Limits Agencies’ “Guidance,” WASH. POST, Jan. 30, 2007, at
D1 (discussing some of the initial reactions).  Strangely, OMB did not expressly
exempt the FDA from the Bulletin.
94. See Exec. Order No. 13,422, Further Amendment to Executive Order 12866 on
Regulatory Planning and Review, 72 Fed. Reg. 2763 (Jan. 18, 2007) (revoked
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guidance documents could have a significant economic impact repre-
sents an uncharacteristically candid admission about how such tech-
nically nonbinding announcements may operate in practice.95  In any
case, the requirement for limited OMB review of economically signifi-
cant guidance was revoked at the outset of the Obama administra-
tion,96 only to get informally resurrected just a couple of months
later,97 which seemed fairly dubious insofar as the Executive Order on
regulatory review originally issued at the outset of the Clinton admin-
istration had (unlike its predecessor) applied solely to genuinely bind-
ing rules.98
2009).  Several members of Congress took issue with this development, though
most of their criticism focused on other aspects of the Executive Order. See Cindy
Skrzycki, Fighting for the Right to the Rules, WASH. POST, July 17, 2007, at D2
(reporting that it triggered three oversight hearings and an appropriations rider
approved by the House to block implementation by OMB).
95. See OMB Bulletin, 72 Fed. Reg. at 3435 (elaborating on “situations in which it
may reasonably be anticipated that a guidance document could lead parties to
alter their conduct in a manner that would have such an economically significant
impact”); id. at 3434 (recognizing that “the impacts of guidance often will be more
indirect and attenuated than binding legislative rules”); see also Notice, Draft
Report to Congress on the Costs and Benefits of Federal Regulations, 67 Fed.
Reg. 15,014, 15,034–35 (Mar. 28, 2002) (including an OMB request for public
comments on “problematic guidance documents”).  I wonder whether a reviewing
court would credit such an OMB designation to counter an agency’s ripeness ob-
jection if a party pursued a judicial challenge to a guidance document.
96. See Exec. Order No. 13,497, Revoking Executive Orders 13258 and 13422 Con-
cerning Regulatory Planning and Review, 74 Fed. Reg. 6113 (Jan. 30, 2009); see
also Presidential Memorandum on Regulatory Review, 74 Fed. Reg. 5977 (Jan.
30, 2009) (soliciting agency comments on possible amendments to Pres. Clinton’s
Executive Order 12,866); OMB Notice, Federal Regulatory Review, 74 Fed. Reg.
8819 (Feb. 26, 2009) (inviting public comment on the same).
97. See Peter R. Orszag, Memorandum for the Heads and Acting Heads of Executive
Departments and Agencies, OMB (Mar. 4, 2009), archived at http://perma.unl.
edu/XX8M-5GBR; see also Sunstein, supra note 11, at 1853–54 (elaborating).  At
least one FDA draft guidance document apparently went unnoticed until an advi-
sor to the President caught a news item and demanded that the agency withdraw
it immediately. See Gardiner Harris, White House and the F.D.A. Often at Odds,
N.Y. TIMES, Apr. 3, 2012, at A1 (describing an incident involving posted calorie
counts for movie theater popcorn); see also Notice of Availability, Draft Guidance
for Industry: Questions and Answers Regarding Implementation of the Menu La-
beling Provisions of Section 4205 of the Patient Protection and Affordable Care
Act of 2010, 75 Fed. Reg. 52,426 (Aug. 25, 2010), withdrawn, 76 Fed. Reg. 4360
(Jan. 25, 2011) (reflecting the formal resolution of this episode).
98. See Noe & Graham, supra note 93, at 105.  When the Obama administration
amended Executive Order 12,866, it apparently did not alter this provision or
otherwise suggest any review of guidance documents. See Exec. Order No.
13,563, Improving Regulation and Regulatory Review, 76 Fed. Reg. 3821 (Jan.
18, 2011).  Even so, under the Paperwork Reduction Act (PRA), 44 U.S.C.
§§ 3501–3520 (2012), information collection requests must go through their own
version of a notice-and-comment process even if unconnected to a rulemaking
proceeding, see 5 C.F.R. §§ 1320.5, 1320.10 (2014); Jeffery S. Lubbers, Paperwork
Redux: The (Stronger) Paperwork Reduction Act of 1995, 49 ADMIN. L. REV. 111,
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C. Too Much of a Good Thing at the FDA?
The FDA does not reserve guidance documents for narrow and
technical facets of its work.  Large swaths of important agency activi-
ties depend entirely on such nonbinding pronouncements,99 and in ar-
eas other than those where Congress has expressly invited or
demanded guidance-making.  As elaborated below, these include such
non-trivial issues as direct-to-consumer advertising of prescription
products, indirect advertising to physicians, pharmacy compounding,
and everything having to do with genetically engineered foods.  In
other areas, the FDA uses guidance to update regulations promul-
gated long ago.100  Occasionally, it will issue regulations that invite/
encourage parties to access existing or anticipated future guidance on
a particular subject,101 even though such an arrangement arguably
114–17 (1997).  Under this law, some guidance documents always have required
OMB review. See Seiguer & Smith, supra note 68, at 24 (“If a new guidance has
any paperwork burdens (e.g., additional forms to be filed with FDA), the PRA
demands the same oversight for the guidance as that which applies to a rule,
including oversight by OMB.  While a guidance cannot impose a burden or re-
quire a form because technically it is voluntary, it can trigger a paperwork bur-
den to the extent that information must be reported to FDA.”); see also Notice of
Availability, Guidance for Industry: Guide to Minimize Food Safety Hazards for
Fresh-Cut Fruits and Vegetables, 73 Fed. Reg. 10,037 (Feb. 25, 2008) (“This docu-
ment was issued as a ‘draft final’ guidance [almost one year ago] pending OMB
approval of the collection of information.”). But cf. Mendelson, supra note 12, at
411 n.80 (asserting incorrectly that the PRA does not apply to guidance docu-
ments); Raso, supra note 13, at 788 & n.16 (making the same mistake).
99. See Rakoff, supra note 31, at 167–68 (“What the FDA did [with its GGPs] was to
take the APA’s lenient attitude toward interpretative rules and policy statements
and convert it into a wholly alternative system of regulation. . . .  [G]uidance
documents are meant to be statements of no legal consequence but immense prac-
tical consequence about virtually everything the agency regulates.”).
100. See infra notes 103–06 and accompanying text; see also Noah, supra note 61, at
294–99 (discussing the practice of interpreting rather than amending rules).
Conversely, rather than going to the trouble of revising a recently finalized gui-
dance, the FDA may issue a draft guidance further explaining it. See, e.g., Notice
of Availability, Draft Guidance for Industry on Abbreviated New Drug Applica-
tions: Stability Testing of Drug Substances and Products, Questions and An-
swers, 78 Fed. Reg. 52,931 (Aug. 27, 2013).
101. See, e.g., 21 C.F.R. § 101.9(b)(7)(vi) (2014) (serving sizes for nutrition labeling);
id. § 170.39(h) (substances that migrate from food-contact articles); id.
§ 310.501(e) (patient labeling for oral contraceptives); id. § 310.515(d) (patient la-
beling for drug products containing estrogen); id.§ 314.50 (format and content of
applications for new drug approval); id. § 500.80(a) (carcinogens in food-produc-
ing animals); id. § 530.13(c) (compounding of veterinary drugs); id. § 822.12
(postmarket surveillance for medical devices); see also Henley v. FDA, 77 F.3d
616, 618, 621 (2d Cir. 1996) (rejecting a challenge to the FDA’s revised regulation
for patient labeling to accompany oral contraceptives, finding merit to the as-
serted need for flexibility in updating such information); infra note 138 (listing
more general codified cross-references).  References to specific guidance docu-
ments appear throughout the FDA’s medical device classification regulations, see
21 C.F.R. pts. 862–892 (2014), but these are unobjectionable insofar as Congress
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conflicts with a pair of rules that the Office of the Federal Register
imposes on agency regulations that use incorporation by reference.102
Nowadays, it seems, legislative rulemaking only happens when Con-
gress insists on that course of action.
For instance, rather than go to the trouble of amending its then 25-
year-old regulations delineating “current” good manufacturing prac-
tices (cGMPs) for drugs, the FDA decided to issue guidance for the
adoption of innovative quality control technologies by the pharmaceu-
tical industry.103  Similarly, even as prescription drug advertising has
become increasingly sophisticated,104 reflecting greater ingenuity and
the emergence of brand new media such as the Internet, the FDA has
not revised regulations that it issued during the 1960s,105 relying in-
stead on various guidance documents.106  At the same time, the Office
of the Inspector General (OIG) of the Department of Health and
Human Services (HHS), acting under its authority to investigate
fraud and abuse involving the Medicare and Medicaid programs, is-
expressly authorized the use of such guidelines as “special controls” for Class II
devices, see 21 U.S.C. § 360c(a)(1)(B) (2012).
102. See 1 C.F.R.§ 51.1(f) (2014) (requiring that the cross-referenced material already
exist); id. § 51.7(b) (barring incorporation by reference of materials published by
the agency itself); see also Emily S. Bremer, Incorporation by Reference in an
Open-Government Age, 36 HARV. J.L. & PUB. POL’Y 131, 142 (2012) (“This rule
prevents agencies from pulling regulations out of the CFR, publishing them else-
where (for example, in a pamphlet or on the agency’s website), and then incorpo-
rating them by reference.”); id. at 184–86 (discussing prohibitions on “dynamic”
as opposed to static incorporations by reference).
103. See Leila Abboud & Scott Hensley, Factory Shift: New Prescription for Drug Mak-
ers, WALL ST. J., Sept. 3, 2003, at A1.
104. See Lars Noah, Medicine’s Epistemology: Mapping the Haphazard Diffusion of
Knowledge in the Biomedical Community, 44 ARIZ. L. REV. 373, 430–34 (2002).
105. See Lars Noah, Advertising Prescription Drugs to Consumers: Assessing the Regu-
latory and Liability Issues, 32 GA. L. REV. 141, 146 n.21 (1997) (“[A]fter originally
promulgating its advertising regulations in the 1960s, . . . the Agency has pre-
ferred to issue technically nonbinding policy statements and guidelines . . . .”).
The sole exception responded to an explicit congressional directive to issue imple-
menting rules for a new statutory provision. See Final Rule, Dissemination of
Information on Unapproved/New Uses for Marketed Drugs, Biologics, and De-
vices, 63 Fed. Reg. 64,556 (Nov. 20, 1998) (codified at 21 C.F.R. pt. 99 (2006)),
rescinded, 73 Fed. Reg. 9342 (Feb. 20, 2008); see also infra note 112 and accompa-
nying text (discussing a still pending NPRM to implement a 2007 statutory
amendment on direct-to-consumer advertising of prescription products).
106. See, e.g., Notice of Availability, Draft Guidances for Industry on Improving Infor-
mation About Medical Products and Health Conditions, 69 Fed. Reg. 6308 (Feb.
10, 2004); Notice of Availability, Guidance for Industry on Consumer-Directed
Broadcast Advertisements, 64 Fed. Reg. 43,197 (Aug. 9, 1999); Request for Com-
ments, Prescription Drug Advertising and Promotional Labeling; Development
and Use of FDA Guidance Documents, 62 Fed. Reg. 14,912, 14,913–16 (Mar. 28,
1997); infra notes 116–28 (discussing guidance documents that address industry
distribution of textbooks and article reprints to physicians as well as sponsorship
of continuing medical education programs).
2014] GOVERNANCE BY THE BACKDOOR 115
sued guidelines to restrict drug and device industry marketing
practices.107
Direct-to-consumer advertising (DTCA) of prescription drugs and
medical devices has expanded over the last quarter of a century.108  In
1995, in the course of soliciting public feedback, the FDA conceded
that “[t]here are no regulations that pertain specifically to consumer-
directed promotional materials.”109  Almost two decades later, that
statement remains true, though numerous guidance documents now
address different aspects of the practice.110  In 2007, in addition to
lifting the burdensome formal rulemaking requirements that had ap-
plied to prescription drug advertising regulations for almost half a
century, Congress granted the agency greater authority in this area,
though only after the FDA issues binding rules,111 which it has pro-
posed but not yet finalized.112  In contrast, after the agency repeatedly
107. See Notice, OIG Compliance Program Guidance for Pharmaceutical Manufactur-
ers, 68 Fed. Reg. 23,731 (May 5, 2003); Robert Pear, Drug Industry Is Told to
Stop Gifts to Doctors, N.Y. TIMES, Oct. 1, 2002, at A1; see also CAL. HEALTH &
SAFETY CODE § 119402 (2012) (requiring adoption of compliance programs that
satisfy the OIG guidelines).
108. See Request for Comment, Healthcare Professional Survey of Prescription Drug
Promotion, 77 Fed. Reg. 61,761, 61,762 (Oct. 11, 2012); Keith J. Winstein & Su-
zanne Vranica, Drug Firms’ Spending on Consumer Ads Fell 8% in ’08, a Rare
Marketing Pullback, WALL ST. J., Apr. 16, 2009, at B2 (“U.S. spending on such
drug ads hit a peak of $4.8 billion in 2007 . . . .”).
109. Notice of Public Hearing, Direct-to-Consumer Promotion, 60 Fed. Reg. 42,581,
42,583 (Aug. 16, 1995).
110. See Notice of Availability, Draft Guidance for Industry on Presenting Risk Infor-
mation in Prescription Drug and Medical Device Promotion, 74 Fed. Reg. 25,245
(May 27, 2009); Notice of Public Hearing, Consumer-Directed Promotion of Regu-
lated Medical Products, 70 Fed. Reg. 54,054 (Sept. 13, 2005) (summarizing mile-
stones in the agency’s supervision of the practice); Notice of Availability, Draft
Guidances for Industry on Improving Information About Medical Products and
Health Conditions, 69 Fed. Reg. 6308 (Feb. 10, 2004), comment period reopened,
69 Fed. Reg. 30,945 (June 1, 2004); Notice of Availability, Guidance for Industry
on Consumer-Directed Broadcast Advertisements, 64 Fed. Reg. 43,197 (Aug. 9,
1999); see also Lars Noah, This Is Your Products Liability Restatement on Drugs,
74 BROOK. L. REV. 839, 902 n.275 (2009) (“More than a decade has passed since
the FDA announced plans to issue a notice of proposed rulemaking to address the
issue.”).
111. See Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85,
§ 901(d)(2), 121 Stat. 823, 939 (codified at 21 U.S.C. § 353b(a) (2012)) (authoriz-
ing advance review of broadcast DTCA); see also id. § 901(d)(6), 121 Stat. at 942
(codified at 21 U.S.C. § 352(n) (2012)) (eliminating the formal rulemaking proce-
dures previously applicable to drug advertising regulations).
112. See Notice of Proposed Rulemaking, Direct-to-Consumer Prescription Drug Ad-
vertisements; Presentation of the Major Statement in Television and Radio Ad-
vertisements in a Clear, Conspicuous, and Neutral Manner, 75 Fed. Reg. 15,376
(proposed Mar. 29, 2010) (to be codified at 21 C.F.R. § 202.1(e)), comment period
reopened, 77 Fed. Reg. 16,973 (Mar. 23, 2012).
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failed to tackle online promotional efforts,113 Congress recently de-
manded that it issue guidance dealing with that subject.114
More than twenty years ago, the FDA became concerned about ef-
forts by pharmaceutical and medical device manufacturers to promote
“off-label” uses to health care professionals in the guise of educational
outreach—primarily through the distribution of textbooks and re-
prints of articles (so-called “enduring materials”) and sponsorship of
continuing medical education (CME) programs.115  In 1992, the
agency issued a “draft policy statement” to inform the industry that it
might regard such activities as unlawful product promotions unless
certain steps were taken to ensure editorial independence.116  Al-
though characterized at the time as a “safe harbor,”117 these an-
nouncements were part of a crackdown on perceived industry excesses
rather than an enlightened effort to liberalize existing prohibitions
that seemed unduly restrictive.
The FDA formulated its off-label promotion policies in a manner
designed to evade normal administrative law constraints.  The draft
policy statement evolved into a pair of draft guidance documents on
113. See Notice of Hearing, Promotion of Food and Drug Administration-Regulated
Medical Products Using the Internet and Social Media Tools, 74 Fed. Reg. 48,083
(Sept. 21, 2009); Randy Gray, Note, One Click Is Enough: Satisfying FDA’s Fair
Balance in the Highly-Regulated Marketplace, 39 RUTGERS COMPUTER & TECH.
L.J. 95, 98 (2013) (“Despite contemplating social media regulations since 1996,
the FDA . . . has not issued any specific regulations for the industry to follow
regarding social media.  Instead, it has been the FDA’s policy to attempt to regu-
late the industry’s use of the social media through letters complaining of their
promotional activity.” (footnote omitted)); id. at 103, 106–08 (discussing several
of these warning letters); id. at 111, 113–15 (noting repeated failures by the FDA
to issue a promised guidance document); Christian Torres, Citing Risks, Drug
Firms Going Offline, WASH. POST, Aug. 14, 2011, at A3 (same).
114. See Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-
144, § 1121, 126 Stat. 993, 1112 (2012); see also Notice of Availability, Draft Gui-
dance for Industry on Fulfilling Regulatory Requirements for Postmarketing
Submissions of Interactive Promotional Media for Prescription Human and
Animal Drugs and Biologics, 79 Fed. Reg. 2449 (Jan. 14, 2014) (responding to this
directive).
115. See Lars Noah, Truth or Consequences?: Commercial Free Speech vs. Public
Health Promotion (at the FDA), 21 HEALTH MATRIX 31, 69–70 (2011).
116. See Notice, Draft Policy Statement on Industry-Supported Scientific and Educa-
tional Activities, 57 Fed. Reg. 56,412 (Nov. 27, 1992).  In the wake of strong in-
dustry reaction to the Draft Policy Statement, the FDA twice extended the
comment deadline. See Extension of Comment Period, Draft Policy Statement on
Industry-Supported Scientific and Educational Activities, 58 Fed. Reg. 6126 (Jan.
26, 1993); Request for Comments, Citizen Petition Regarding the Food and Drug
Administration’s Policy on Promotion of Unapproved Uses of Approved Drugs
and Devices, 59 Fed. Reg. 59,820 (Nov. 18, 1994).
117. See David G. Adams, FDA Regulation of Communications on Pharmaceutical
Products, 24 SETON HALL L. REV. 1399, 1409–17 (1994) (describing the origins of
this policy, and defending its constitutionality).
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enduring materials published in 1995,118 which were finalized one
year later,119 and into a final guidance document on CME programs
published in 1997.120  Although not formally binding, even in their fi-
nal form,121 these various FDA announcements unmistakably sought
to alter the behavior of pharmaceutical and medical device companies.
A federal district court understood these realities when, in the first
phase of constitutional litigation brought by the Washington Legal
Foundation (WLF), it rejected the agency’s claim that the challenge to
the draft policy statement was not ripe for judicial review; Judge Lam-
berth speculated that the FDA would “threaten[ ] (but never actually
initiat[e]) enforcement procedures against companies which failed to
comply with the agency’s de facto policy.”122
Only after Congress intervened in 1997, by enacting a provision
that required the issuance of implementing regulations,123 did the
FDA bother to undertake notice-and-comment rulemaking to promul-
gate formally binding requirements to control industry dissemination
of enduring materials describing off-label uses of drugs and medical
devices.124  Although the WLF litigation continued,125 the agency ulti-
mately managed to prevail on appeal by offering a somewhat con-
trived interpretation of its policies.126  When the statutory provision
118. See Notice, Advertising and Promotion; Draft Guidances, 60 Fed. Reg. 62,471
(Dec. 6, 1995).
119. See Notice, Advertising and Promotion; Guidances, 61 Fed. Reg. 52,800 (Oct. 8,
1996).
120. See Notice, Final Guidance on Industry-Supported Scientific and Educational Ac-
tivities, 62 Fed. Reg. 64,074 (Dec. 3, 1997).  The agency had received more than
two hundred comments on the 1992 draft policy statement and a related citizen
petition, see id. at 64,074, and the preamble accompanying this guidance docu-
ment, which offered fairly detailed responses to these comments, occupied almost
twenty pages in the Federal Register, see id. at 64,074–92.
121. See, e.g., id. at 64,094 n.1 (“This guidance . . . does not operate to bind FDA or the
industry . . . .”).
122. Wash. Legal Found. v. Kessler, 880 F. Supp. 26, 34 (D.D.C. 1995); see also id. at
36 (“[F]ew if any companies are willing to directly challenge the FDA in this man-
ner. . . .  [M]anufacturers are most reluctant to arouse the ire of such a powerful
agency.”).
123. See Pub. L. No. 105-115, § 401(a), 111 Stat. 2296, 2356–64 (1997) (codified at 21
U.S.C. § 360aaa (2006)).
124. See Final Rule, Dissemination of Information on Unapproved/New Uses for Mar-
keted Drugs, Biologics, and Devices, 63 Fed. Reg. 64,556 (Nov. 20, 1998) (codified
at 21 C.F.R. pt. 99 (2006)).
125. See Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51 (D.D.C. 1998), amended
by 36 F. Supp. 2d 16 (D.D.C. 1999), amended sub nom. Wash. Legal Found. v.
Henney, 56 F. Supp. 2d 81 (D.D.C. 1999), vacated in part and appeal dismissed,
202 F.3d 331 (D.C. Cir. 2000).
126. See Lars Noah, What’s Wrong with “Constitutionalizing Food and Drug Law”?, 75
TUL. L. REV. 137, 146–48 (2000); see also Notice, Decision in Washington Legal
Foundation v. Henney, 65 Fed. Reg. 14,286 (Mar. 16, 2000) (memorializing the
position that the agency had taken on appeal).  Although the appellate court had
left parts of the district court’s injunction in place, see Wash. Legal Found. v.
118 NEBRASKA LAW REVIEW [Vol. 93:89
sunset in 2006, the FDA opted to rescind rather than amend the im-
plementing regulation,127 which it then replaced with a substantially
similar (though, of course, technically nonbinding) guidance docu-
ment.128  It seems at least mildly curious that the agency would think
it appropriate to use a guidance document to address a complex and
contentious issue of this sort after the matter previously had required
a special (though temporary) legislative amendment coupled with im-
plementing regulations.129
In connection with the compounding of drug products, the FDA has
struggled to draw the line between the permissible practice of phar-
macy and impermissible efforts to flout federal licensing require-
ments, eventually announcing its approach to enforcement in a 1992
“Compliance Policy Guide” (CPG).130  Proponents of compounding
failed in mounting a procedural challenge to this announcement.131
Henney, 202 F.3d 331, 334 n.4 & 337 n.7 (D.C. Cir. 2000), on remand Judge Lam-
berth concluded that nothing remained of his original order, see Wash. Legal
Found. v. Henney, 128 F. Supp. 2d 11, 15 (D.D.C. 2000); cf. id. (“[T]he issue re-
mains 100% unresolved, and the country’s drug manufacturers are still without
clear guidance as to their permissible conduct.  To say that FDA’s March 16, 2000
Notice finally clarifies the situation is a farce; the Notice specifically invites a
constitutional challenge to each and every one of its enforcement actions.”).  A
First Amendment challenge to a prosecution for off-label promotion recently suc-
ceeded. See United States v. Caronia, 703 F.3d 149 (2d Cir. 2012).
127. See Notice of Availability, Draft Guidance for Industry on Good Reprint Practices
for the Distribution of Medical Journal Articles and Medical or Scientific Refer-
ence Publications on Unapproved New Uses of Approved Drugs and Approved or
Cleared Medical Devices, 73 Fed. Reg. 9342 (Feb. 20, 2008); see also Notice of
Availability, Draft Guidance for Industry on Responding to Unsolicited Requests
for Off-Label Information About Prescription Drugs and Medical Devices, 76 Fed.
Reg. 82,303 (Dec. 30, 2011) (issuing a related guidance).
128. See Notice of Availability, Guidance for Industry on Good Reprint Practices for
the Distribution of Medical Journal Articles and Medical or Scientific Reference
Publications on Unapproved New Uses of Approved Drugs and Approved or
Cleared Medical Devices, 74 Fed. Reg. 1694 (Jan. 13, 2009); see also Noah, supra
note 115, at 80–81 (discussing this guidance); id. at 70 n.169, 77–80 (explaining
that the 1997 guidance document on CME programs had remained unchanged
during this time).  Five years later, the FDA further diminished the authoritative
status of its policy. See Notice of Availability, Revised Draft Guidance for Indus-
try on Distributing Scientific and Medical Publications on Unapproved New
Uses—Recommended Practices, 79 Fed. Reg. 11,793 (Mar. 3, 2014).
129. See Michael Jon Andersen, Note, Bound Guidance: FDA Rulemaking for Off-La-
bel Pharmaceutical Drug Marketing, 60 CASE W. RES. L. REV. 531, 547 (2010); see
also id. at 542–44 (explaining that the draft guidance document had elicited sev-
eral adverse comments, including from at least one member of Congress, and that
the agency partly took these into account in the final version).
130. See Notice of Availability, Compliance Policy Guide: Manufacture, Distribution,
and Promotion of Adulterated, Misbranded, or Unapproved New Drugs for
Human Use by State-Licensed Pharmacies, 57 Fed. Reg. 10,906 (Mar. 31, 1992).
131. See Prof’ls & Patients for Customized Care v. Shalala, 56 F.3d 592, 599 (5th Cir.
1995); see also Takhar v. Kessler, 76 F.3d 995, 1002 (9th Cir. 1996) (rejecting
procedural challenge to CPG on off-label use of veterinary drugs).
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Five years later, Congress codified much of the agency’s existing infor-
mal policy, though with some modifications.132  Five years after enact-
ment, the Supreme Court invalidated the provision on First
Amendment grounds,133 leaving the agency to issue a revised version
of its older CPG.134  In 2012, after a nationwide outbreak of fungal
meningitis led to numerous deaths in patients who had received injec-
tions of a steroid compounded by a pharmacy in Massachusetts, mem-
bers of Congress pressed FDA officials to explain the agency’s
somewhat indeterminate policy.135
Responsiveness to scientific advances represents a common justifi-
cation for guidance.136  At one level, the FDA wants to specify details
about how it will evaluate the safety and effectiveness of regulated
products.  For instance, the agency has used guidance to define appro-
priate forms of toxicity testing for food and color additives.137  Simi-
132. Pub. L. No. 105-115, § 127(a), 111 Stat. 2296, 2328 (codified at 21 U.S.C. § 353a
(2012)).
133. See Thompson v. W. States Med. Ctr., 535 U.S. 357, 372–77 (2002); see also Noah,
supra note 115, at 53–65 (critiquing the decision).
134. See Notice of Availability, Pharmacy Compounding Compliance Policy Guide, 67
Fed. Reg. 39,409 (June 7, 2002); see also Wedgewood Vill. Pharmacy, Inc. v.
United States, 421 F.3d 263, 272–73 (3d Cir. 2005) (granting deference to this
CPG even though not promulgated through notice-and-comment rulemaking); cf.
Med. Ctr. Pharmacy v. Mukasey, 536 F.3d 383, 390–91, 401–06 (5th Cir. 2008)
(concluding that the unconstitutional advertising restriction was severable from
the remainder of FDAMA’s compounding limitations, rendering the CPG
irrelevant).
135. See Michael Snow, Note, Seeing Through the Murky Vial: Does the FDA Have the
Authority to Stop Compounding Pharmacies from Pirate Manufacturing?, 66
VAND. L. REV. 1609, 1613, 1636–37 (2013); Timothy W. Martin et al., Outbreak
Spurs Calls for New Controls, WALL ST. J., Oct. 9, 2012, at A1.  For a vaguely
parallel trajectory involving another guideline, see Amy Gaither, Comment, Over
the Counter, Under the Radar: How the Zicam Incident Came About Under FDA’s
Historic Homeopathic Exception, 62 ADMIN. L. REV. 487, 502–09 (2010) (discuss-
ing the 1988 CPG that largely exempted homeopathic remedies from regulation
as new drugs).  Recently the FDA also has used guidance documents to address a
problem that partly explains the upsurge in pharmacy compounding. See, e.g.,
Notice of Availability, Guidance for Industry on Planning for the Effects of High
Absenteeism to Ensure Availability of Medically Necessary Drug Products, 76
Fed. Reg. 14,025 (Mar. 15, 2011); Notice of Availability, Product Shortage Report,
76 Fed. Reg. 68,770 (Nov. 7, 2011). See generally Lars Noah, Triage in the Na-
tion’s Medicine Cabinet: The Puzzling Scarcity of Vaccines and Other Drugs, 54
S.C. L. REV. 741 (2003).
136. See Seiguer & Smith, supra note 68, at 23 (“In many cases, guidances are used to
communicate very detailed—often scientific—information to FDA’s constituen-
cies.  Those interviewed agreed that due to the rapid pace of scientific advance-
ment, guidances—with their less rigorous review and clearance process . . . and
their nonbinding nature—provide the best means of providing information to as-
sist industry in understanding and complying with regulatory requirements.”).
137. See Notice of Availability, Draft Revised “Toxicological Standards for Food and
Color Additive Safety Evaluation,” 58 Fed. Reg. 16,536 (Mar. 29, 1993); Simpson
v. Young, 854 F.2d 1429, 1435 (D.C. Cir. 1988) (holding that the FDA need not
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larly, it has issued guidance to describe how to conduct acceptable
clinical trials of particular classes of drugs and devices.138
At another level, profound scientific advances may confront the
FDA with difficult regulatory questions that require some time to re-
solve, and, at least initially, it may prefer a flexible response.139  Over
the last quarter of a century, for instance, the agency has relied exclu-
sively on guidance documents to address the various issues that have
arisen with genetically engineered (GE) plants,140 animals,141 and ap-
demand adherence to these guidelines given the “permissive language in the
manual”); Edward F. Bouchard, The Food and Drug Administration’s Redbook:
The Practical Implications for Business Practices, 39 FOOD DRUG COSM. L.J. 211
(1984).
138. See, e.g., Berlex Labs., Inc. v. FDA, 942 F. Supp. 19, 26–27 (D.D.C. 1996) (re-
jecting a procedural challenge to a guidance document on the acceptability of
clinical trials with comparable products); Notice of Availability, Guidance for In-
dustry on Residual Drug in Transdermal and Related Drug Delivery Systems, 76
Fed. Reg. 51,038 (Aug. 17, 2011); see also 21 C.F.R. § 312.23(a)(8) (2014) (“Gui-
dance documents are available from FDA that describe ways in which these
[preclinical drug testing] requirements may be met.”); id. § 314.105(c) (“FDA
makes its views on drug products and classes of drugs available through guidance
documents, recommendations, and other statements of policy.”); id. § 314.445(a)
(“FDA has made available guidance documents . . . to help you to comply with
certain requirements of this part [governing new drug approval].”); id. § 316.50
(same, for orphan drugs); id. § 601.29 (same, for biologics); id. § 814.20(g)
(premarket approval applications for medical devices); Christopher L.
Hagenbush, How the Food and Drug Administration and Industry Use Guide-
lines in Defining and Interpreting Statutory Requirements, 38 FOOD DRUG COSM.
L.J. 177, 178–79 (1983) (describing the FDA’s decision to issue guidelines rather
than regulations concerning clinical testing); Richard A. Merrill, The Architecture
of Government Regulation of Medical Products, 82 VA. L. REV. 1753, 1778–81,
1779 n.79, 1848 (1996) (discussing the importance to applicants of reliable FDA
guidance on acceptable clinical study designs).  For a recent example, see Notice
of Availability, Draft Guidance for Industry on Alzheimer’s Disease: Developing
Drugs for the Treatment of Early Stage Disease, 78 Fed. Reg. 9396 (Feb. 8, 2013);
Gina Kolata, F.D.A. Plans to Loosen Rules on Alzheimer’s Drug Approval, N.Y.
TIMES, Mar. 14, 2013, at A1.
139. See Seiguer & Smith, supra note 68, at 22 (“[I]n circumstances where the science
or technology may be evolving rapidly, such that more speed and flexibility are
needed, guidances are likely to be considered the best solution.”).
140. See, e.g., Notice, Guidance on Consultation Procedures: Foods Derived from New
Plant Varieties, 76 Fed. Reg. 9020 (Feb. 16, 2011); Notice of Availability, Gui-
dance for Industry; Recommendations for the Early Food Safety Evaluation of
New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food
Use, 71 Fed. Reg. 35,688 (June 21, 2006); Notice of Availability, Draft “Guidance
for Industry: Drugs, Biologics, and Medical Devices Derived from Bioengineered
Plants for Use in Humans and Animals,” 67 Fed. Reg. 57,828 (Sept. 12, 2002);
Notice, Statement of Policy: Foods Derived from New Plant Varieties, 57 Fed.
Reg. 22,984 (May 29, 1992); see also Alliance for Bio-Integrity v. Shalala, 116 F.
Supp. 2d 166 (D.D.C. 2000) (rejecting procedural and substantive challenges to
the FDA’s 1992 policy statement); Lars Noah, Managing Biotechnology’s
[R]evolution: Has Guarded Enthusiasm Become Benign Neglect?, 11 VA. J.L. &
TECH. 4, ¶¶ 31–35 (2006) (discussing this statement); id. ¶ 42 (explaining that a
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propriate labeling of food products derived from these sources.142  The
FDA has responded in a similar fashion to advances in pharmacoge-
nomics,143 nanotechnologies,144 and xenotransplantation.145  At some
set of regulations proposed at the very end of the Clinton administration went
nowhere).
141. See Notice of Availability, Guidance for Industry on Regulation of Genetically
Engineered Animals Containing Heritable Recombinant DNA Constructs, 74
Fed. Reg. 3057 (Jan. 16, 2009); Lars Noah, Whatever Happened to the
“Frankenfish”?: The FDA’s Foot-dragging on Transgenic Salmon, 65 ME. L. REV.
606, 611–12 (2013); cf. David Pierson, FDA to Phase out Antibiotic Use by Farms;
Employing the Drugs for Boosting Animal Growth Will Be Curbed to Fight In-
creasing Resistance in Humans, L.A. TIMES, Dec. 12, 2013, at A1 (reporting that
the agency finalized a guidance calling for the voluntary cessation of non-thera-
peutic uses of antimicrobials in livestock within three years); Editorial, FDA
Moves Timidly Against Antibiotic Use on Farms, USA TODAY, Dec. 26, 2013, at
10A (criticizing this effort as woefully inadequate).
142. See Notice of Availability, Draft Guidance for Industry: Voluntary Labeling Indi-
cating Whether Foods Have or Have Not Been Developed Using Bioengineering,
66 Fed. Reg. 4839 (Jan. 18, 2001); Notice of Availability, Interim Guidance on the
Voluntary Labeling of Milk and Milk Products from Cows that Have Not Been
Treated with Recombinant Somatotropin, 59 Fed. Reg. 6279 (Feb. 10, 1994); Lars
Noah, Genetic Modification and Food Irradiation: Are Those Strictly on a Need-
to-Know Basis?, 118 PENN. ST. L. REV. (forthcoming June 2014); see also Ariana
Eunjung Cha, New Salvo Launched in GMO Labeling Debate, WASH. POST, Oct.
20, 2013, at A3 (“The FDA has yet to finalize a 12-year-old draft guidance docu-
ment outlining the labeling of foods that contain genetically modified ingredi-
ents.”); cf. 21 C.F.R. § 101.29 (1996) (addressing kosher food labeling), revoked,
Food and Cosmetic Labeling; Revocation of Certain Regulations, 62 Fed. Reg.
43,071, 43,072–73 (Aug. 12, 1997) (explaining that this rule never provided any-
thing beyond general guidance in the first place and would be replaced with a
CPG).
143. See, e.g., Notice of Availability, Guidance for Industry on Clinical Pharmacoge-
nomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommen-
dations for Labeling, 78 Fed. Reg. 5816 (Jan. 28, 2013); Notice of Availability,
Companion to Guidance for Industry on Pharmacogenomic Data, 72 Fed. Reg.
49,722 (Aug. 29, 2007); Notice of Availability, Guidance for Industry on
Pharmacogenomic Data Submissions, 70 Fed. Reg. 14,698 (Mar. 23, 2005). See
generally Lars Noah, The Coming Pharmacogenomics Revolution: Tailoring
Drugs to Fit Patients’ Genetic Profiles, 43 JURIMETRICS J. 1 (2002).
144. See, e.g., Notice of Availability, Draft Guidance for Industry: Safety of Nano-
materials in Cosmetic Products, 77 Fed. Reg. 24,722 (Apr. 25, 2012); Notice of
Availability, Draft Guidance for Industry: Considering Whether an FDA-Regu-
lated Product Involves the Application of Nanotechnology, 76 Fed. Reg. 34,715
(June 14, 2011).
145. See, e.g.,  Notice of Availability, Medical Devices Containing Materials Derived
from Animal Sources (Except for In Vitro Diagnostic Devices); Draft Guidance for
Industry and Food and Drug Administration Staff, 79 Fed. Reg. 3826 (Jan. 23,
2014); Notice of Availability, Guidance for Industry: Source Animal, Product,
Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Prod-
ucts in Humans, 68 Fed. Reg. 16,542 (Apr. 4, 2003); Notice of Availability, Draft
Guidance for Industry: Precautionary Measures to Reduce the Possible Risk of
Transmission of Zoonoses by Blood and Blood Products from Xenotransplantation
Product Recipients and Their Intimate Contacts, 67 Fed. Reg. 6266 (Feb. 11,
2002); Notice of Availability, Guidance for Industry: Public Health Issues Posed
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point, the steep learning curve should begin to plateau, and a matur-
ing industry might benefit from the greater clarity provided by bind-
ing and more stable pronouncements from the agency.146  So long as
guidance documents manage to communicate the FDA’s evolving ex-
pectations reasonably well and secure voluntary adherence, however,
the agency may have little reason to formalize its policies and subject
them to unwelcome external scrutiny.
III. SECURING ADHERENCE TO ANNOUNCED
(AND UNANNOUNCED) POLICIES
If guidance documents technically do not bind anyone, then why do
regulated entities not simply ignore these announcements?  Moreover,
if the FDA communicates its expectations privately rather than
through guidance,147 then why would regulated entities pay any at-
tention whatsoever? As explained in this Part, companies subject to
the agency’s jurisdiction ignore such informal expressions of policy—
whether or not announced in a public document—at their peril.
Congress originally granted the FDA only limited and procedurally
cumbersome mechanisms for securing compliance with the statute:
product seizures, injunctions, and criminal penalties.148 Apart from
procedural hurdles, formal agency enforcement actions face a form of
Executive branch scrutiny; instead of having to run things by OMB,
the FDA must secure the concurrence of the Department of Justice
(DOJ) because the agency lacks any independent litigation author-
by the Use of Nonhuman Primate Xenografts in Humans, 64 Fed. Reg. 16,743
(Apr. 6, 1999).
146. See Martha J. Carter, The Ability of Current Biologics Law to Accommodate
Emerging Technologies, 51 FOOD & DRUG L.J. 375, 376 (1996) (“While the FDA
has made a good faith effort to provide guidance to industry and to solicit indus-
try’s feedback, it is disquieting to note that the entire field of biotechnology is
being regulated without notice and comment rulemaking.”); id. at 377 (noting
that “[g]uidelines are much easier to change than regulations”); Noah, supra note
140, ¶ 43 (“Although flexibility in dealing with an emerging technology has obvi-
ous advantages, there is a case to be made for establishing clearer rules for
bioengineered food products.”); Andrew Pollack, Without U.S. Rules, Biotech Food
Lacks Investors, N.Y. TIMES, July 30, 2007, at A1.
147. Cf. 21 C.F.R. § 10.115(b)(3) (2014) (excluding from GGPs “warning letters . . . or
other communications directed to individual persons or firms”).
148. See 21 U.S.C. §§ 332–334 (2012).  The FDA enjoys largely unreviewable discre-
tion in deciding whether and how to exercise its enforcement powers. See Heck-
ler v. Chaney, 470 U.S. 821, 831–32 (1985); see also United States v. Sage
Pharm., Inc., 210 F.3d 475, 480 (5th Cir. 2000) (holding that the FDA could target
one firm for selling unapproved new drugs even though it had not yet acted
against others who distributed substantially similar products); Schering Corp. v.
Heckler, 779 F.2d 683, 685–87 (D.C. Cir. 1985) (rejecting as unreviewable a phar-
maceutical company’s challenge to a settlement between the FDA and a
competitor).
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ity.149  Separately, Congress has delegated to the agency increasingly
elaborate licensing powers, but these also came with demanding pro-
cedures.150  The FDA has, however, deployed these various tools in
creative ways: for instance, the agency may threaten to impose a sanc-
tion or withhold a license in the hopes of encouraging “voluntary” com-
pliance with a request that the agency would find difficult to impose
directly on a regulated entity.151
Such “arm-twisting” succeeds, and evades judicial or other scru-
tiny, in part because companies in pervasively regulated industries
believe that they cannot afford to resist agency demands.152  For in-
stance, some critics have accused the FDA of retaliating against firms
that fail to cooperate.153  Whether or not such charges are accurate,
149. See United States v. Gel Spice Co., 773 F.2d 427, 429 (2d Cir. 1985); Charles R.
McConachie, The Role of the Department of Justice in Enforcing the Federal Food,
Drug and Cosmetic Act, 31 FOOD DRUG COSM. L.J. 333 (1976); Vandya
Swaminathan & Matthew Avery, FDA Enforcement of Criminal Liability for
Clinical Investigator Fraud, 4 HASTINGS SCI. & TECH. L.J. 325, 350 (2012); see
also Neal Devins & Michael Herz, The Uneasy Case for Department of Justice
Control of Federal Litigation, 5 U. PA. J. CONST. L. 558, 570 (2003) (noting the
following common justification for this arrangement: “[B]ecause the Attorney
General sees the big picture—and sees it with the same eyes as the President—
centralization will ensure that representation is consistent with the broader pol-
icy concerns of the Administration.”); id. at 577–83 (elaborating on and critiquing
this claim); id. at 566 (explaining “that one reason for agencies’ strong preference
for administrative enforcement is freedom from DOJ oversight and control”).
150. See Merrill, supra note 138, at 1757–58, 1762, 1764–66; cf. id. at 1864 (“Nor are
FDA’s decisions—to grant, withhold, or delay approval—commonly challenged in
court. . . .  The FDA product approval system is, in short, remarkably free from
conventional legal constraint.”).
151. See Lars Noah, Administrative Arm-Twisting in the Shadow of Congressional
Delegations of Authority, 1997 WIS. L. REV. 873, 874; cf. Novel Procedures in FCC
License Transfer Proceedings: Hearing Before the Subcomm. on Commercial &
Administrative Law of the H. Comm. on the Judiciary, 106th Cong. 29 (2000)
(statement of Professor Lars Noah, University of Florida College of Law).  The
agency has long relied on such techniques. See H. Thomas Austern, Expertise in
Vivo, 15 ADMIN. L. REV. 46, 50, 56 (1963) (discussing informal enforcement by the
FDA through “jaw-boning” and “lifted eyebrow” techniques, which succeed be-
cause of the ever-present threat of criminal sanctions); id. at 52 (“[M]ost of those
regulated do not often dare to challenge an informal assertion of power.”).
152. See, e.g., Chamber of Commerce v. U.S. Dep’t of Labor, 174 F.3d 206, 210 (D.C.
Cir. 1999) (OSHA “is intentionally using the leverage it has by virtue solely of its
power to inspect.  The Directive is therefore the practical equivalent of a rule that
obliges an employer to comply or to suffer the consequences; the voluntary form
of the rule is but a veil for the threat it obscures.”); id. at 212–13 (holding there-
fore that this announcement was not exempt from notice-and-comment rulemak-
ing requirements). See generally Brigham Daniels, When Agencies Go Nuclear: A
Game Theoretic Approach to the Biggest Sticks in an Agency’s Arsenal, 80 GEO.
WASH. L. REV. 442 (2012).
153. See, e.g., Se. Minerals, Inc. v. Harris, 622 F.2d 758, 761, 767 (5th Cir. 1980) (criti-
cizing the agency’s “bureaucratic hubris that confuses abuse of power with rea-
son,” adding that “the FDA’s abuse of its statutory rights of entry and inspection
so as to harass and threaten [the parties] can in no way be condoned”); Allega-
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the perception leads companies to accede to the agency’s wishes even
though they may lack any basis in law or fact.154  Whatever the rea-
son, the FDA has managed to accomplish its goals more efficiently us-
ing what amount to back channels.155  In this manner, as explained in
the sections that follow, the agency has successfully exercised a recall
power not delegated by Congress.  In addition, and without the need to
allege any wrongdoing or threaten formal enforcement action, the
agency has conditioned the granting of licenses on various postap-
proval restrictions either not contemplated in the enabling statute or
without abiding by procedural prerequisites for their imposition.
A. Threats/Offers in the Enforcement Context
During the early 1990s, the FDA negotiated consent decrees with
pharmaceutical companies that it had accused of unlawfully promot-
ing certain prescription drugs.  In one of these cases, a manufacturer
agreed to undertake an extensive corrective advertising campaign and
also to preclear all of its promotional materials with the agency for a
tions of FDA Abuses of Authority: Hearings Before the Subcomm. on Oversight
and Investigations of the H. Comm. on Commerce, 104th Cong. 2 (1995) (state-
ment of Hon. Joe Barton) (suggesting that “these stories are not rare exceptions,”
and adding that “the FDA never forgets who its enemies are”); id. at 9 (statement
of Hon. Thomas J. Bliley, Jr.) (suggesting that “the threat of retaliation is deeply
embedded in the culture of this Agency”). But see id. at 6 (statement of Hon.
Henry A. Waxman) (warning that we should “not base our policy decisions on
anecdotes and hyperbole”); id. at 83 (statement of Hon. John D. Dingell) (noting
that, “upon a fuller review of the five case studies selected by the Majority, claims
of FDA retaliation were decidedly premature”).
154. See, e.g., Hearings, supra note 153, at 70 (testimony of Ronald C. Jankelson, Myo-
Tronics, Inc.) (describing pressures to enter into a consent decree); see also Eliza-
beth C. Price, Teaching the Elephant to Dance: Privatizing the FDA Review Pro-
cess, 51 FOOD & DRUG L.J. 651, 653 (1996) (“The natural response to such alleged
abusive tactics would be to bring suit against the agency, but such a response
might not be in the best interests of the affected company.”); Peter Brimelow &
Leslie Spencer, Food and Drugs and Politics, FORBES, Nov. 22, 1993, at 115 (cit-
ing the results of a survey which found that 84% of respondents failed to press
potentially legitimate complaints against the FDA for fear of retaliation).
155. Recently, one commentator partially endorsed this type of behavior: “Threat re-
gimes . . . are important and are best justified when the industry is undergoing
rapid change—under conditions of ‘high uncertainty.’ . . .  Examples include peri-
ods surrounding a newly invented technology or business model, or a practice
about which little is known.”  Tim Wu, Agency Threats, 60 DUKE L.J. 1841, 1842
(2011) (“Conversely, in mature, settled industries, use of informal procedures is
much harder to justify.”); see also id. at 1848–57 (elaborating, and conceding the
need to guard against abuse).  This passage invokes the same rationales that the
Supreme Court long ago credited when allowing agencies to eschew rulemaking
in favor of formal adjudication! See SEC v. Chenery Corp., 332 U.S. 194, 202–03
(1947).  For an excellent rebuttal of Professor Wu’s essay, see Jerry Brito, “Agency
Threats” and the Rule of Law: An Offer You Can’t Refuse, 37 HARV. J.L. & PUB.
POL’Y 553 (2014).
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period of two years,156 even though the statute generally prohibits
mandatory preclearance of pharmaceutical advertising.157  In another
case, a company agreed to establish an FDA-approved training pro-
gram for its pharmaceutical sales representatives,158 even though the
agency does not appear to have the power to regulate such communi-
cations.159  In these and other cases, explicit FDA threats of especially
burdensome product seizures or injunctions prompted the companies
to accept these unprecedented requirements.160
156. See Syntex Will Run Naprosyn Corrective Ads in 18 Medical Journals and on
“Lifetime” TV in Court-Filed Consent Decree to Halt Arthroprotective Claims, F-
D-C REP., THE PINK SHEET, Oct. 14, 1991, at 6, 7 [hereinafter Syntex Will Run
Corrective Ads], archived at http://perma.unl.edu/4F35-KRGP (reporting that
“[t]he comprehensive scope and breadth of FDA scrutiny set out in the consent
agreement are unprecedented”); see also Bristol Oncology Promotions Will Be
Precleared by FDA for Two Years, F-D-C REP., THE PINK SHEET, June 3, 1991, at
6, archived at http://perma.unl.edu/6FP-8T7K (describing a preclearance require-
ment covering a dozen products in a consent decree negotiated with Bristol-My-
ers Squibb, and adding that “[t]he agency has extracted similar agreements in
recent years”).
157. See 21 U.S.C. § 352(n) (2012) (providing that, “except in extraordinary circum-
stances, no regulation issued under this subsection shall require prior approval
by the Secretary of the content of any advertisement”); see also 21 C.F.R.
§ 202.1(j) (2014) (implementing regulations that call for FDA preclearance of pro-
posed advertisements only if unexpected fatalities or other serious side effects
come to light); Request for Comments, Direct-to-Consumer Promotion, 61 Fed.
Reg. 24,314, 24,315 (May 14, 1996) (disavowing any intent to require routine
preclearance of prescription drug ads); cf. Food and Drug Administration Amend-
ments Act of 2007, Pub. L. No. 110-85, § 901(d)(2), 121 Stat. 823, 939 (codified at
21 U.S.C. § 353b(a) (2012)) (authorizing the adoption of regulations for the ad-
vance review of broadcast DTCA).
158. See Kabi Pharmacia’s Dipentum Consent Decree Requires FDA-Approved Train-
ing Program for Sales Reps, F-D-C REP., THE PINK SHEET, Aug. 9, 1993, at 17,
archived at http://perma.unl.edu/8ALK-T3UV (noting that the “FDA’s involve-
ment in developing a training program is unprecedented”).  Other provisions of
this consent decree required corrective advertising, preclearance of all promo-
tional materials for one year, and reimbursement of the costs of the FDA’s inves-
tigation. See id. at 18.
159. See Lars Noah, Death of a Salesman: To What Extent Can the FDA Regulate the
Promotional Statements of Pharmaceutical Sales Representatives?, 47 FOOD &
DRUG L.J. 309, 322–26 (1992).
160. See, e.g., Syntex Will Run Corrective Ads, supra note 156, at 7 (“To get the Syntex
agreement, FDA is understood to have threatened to seize all of the company’s
stocks of Naprosyn.”); see also Richard M. Cooper, The Need for Oversight of
Agency Policies for Settling Enforcement Actions, 59 ADMIN. L. REV. 835, 840–41
(2007) (“The FDA has no written statement of general policy for its consent de-
crees. . . .  Common provisions of an FDA consent decree include . . . a grant to
FDA of authority, not otherwise provided by the FDCA, to order the company to
take certain types of action if FDA determines that the company has not complied
with the decree . . . .”); id. at 843 (“Organizations commonly view the prospect of
civil litigation against the government and administrative sanctions as far worse
than settling on the government’s terms. . . .  Because organizations almost al-
ways accept such settlements rather than litigate, it is reasonable to infer that
they have little bargaining power.”); cf. id. at 840 (“As part of the price for avoid-
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The FDA routinely issues “warning letters” that allege some regu-
latory infraction and provide the recipient with a limited period of
time to take corrective action (coupled with a threat of formal enforce-
ment proceedings).161  In the case of drugs and medical devices, the
agency used to go further and explain that government purchasing
entities had been advised to stop dealing with the firm in the
meantime.162  Because the federal government represents the single
largest purchaser of prescription drugs in this country, few manufac-
turers could afford to lose these contracts.163  If a company dared to
disagree with the agency’s allegations and chose to pursue a judicial
ing prosecution, [one major drug] company also agreed to endow a chair at Seton
Hall University Law School, which happened to be the alma mater of the U.S.
Attorney.”); Hunnicutt, supra note 33, at 174 (explaining that one FDA consent
decree obligated the regulated entity to abide by nonbinding guidance).
161. See Rebecca Boxhorn, Note, FDA Goes Loko with Warning Letters, 12 MINN. J.L.
SCI. & TECH. 749, 750 (2011) (“Warning Letters generally contain: (1) a determi-
nation that the regulated party is in violation of the FDCA, (2) a demand for
corrective action, (3) a request for response within fifteen days, and (4) a warning
that the receipt of a Warning Letter may hinder future government contracting
opportunities.”).  Congress clearly authorized precisely such informal action by
the FDA. See 21 U.S.C. § 336 (2012) (“Nothing in this chapter shall be construed
as requiring the Secretary to report for prosecution, or for the institution of libel
or injunction proceedings, minor violations of this chapter whenever he believes
that the public interest will be adequately served by a suitable written notice or
warning.”).  The latest enforcement numbers reveal the issuance of 4,882 warn-
ing letters and just 25 seizure or injunction actions. See FDA, ENFORCEMENT STA-
TISTICS SUMMARY (2012), archived at http://perma.unl.edu/XB6S-GWVJ; Andrew
Zajac, Under Obama, a Renewed FDA: The Agency Steps up Its Regulatory Activ-
ity, and the Activism Is Likely to Increase, L.A. TIMES, Oct. 10, 2010, at A11.
162. See Noah, supra note 151, at 886 n.47.  Nowadays the agency uses milder lan-
guage to get the same point across. See FDA, REGULATORY PROCEDURES MANUAL
ch. 4, at 4-17 (2011), archived at http://perma.unl.edu/QA38-EHCV (providing
that letters sent to manufacturers of medical devices should include the following
language: “Federal agencies are advised of all Warning Letters about devices so
that they may take this information into account when considering the award of
contracts.”); id. at 4-18 (providing that letters sent to drug manufacturers should
include the following language: “Other federal agencies may take this Warning
Letter into account when considering the award of contracts.”).  In contrast to its
silence in the FDCA, Congress included procurement freeze provisions in a pair
of prominent environmental statutes. See 33 U.S.C. § 1368 (2012); 42 U.S.C.
§ 7606 (2012).
163. See Boxhorn, supra note 161, at 768 (“Threats by the FDA to inform other govern-
ment agencies . . . of the presence of an outstanding Warning Letter present a
real risk to those pharmaceutical companies that consistently contract with the
government for the sale of their products to Medicare and Medicaid patients.”);
see also Scott Hensley, Big Buyers Push for Steep Price Cuts from Drug Makers,
WALL ST. J., June 22, 2006, at B1 (explaining that, as the health insurer for over
five million individuals, the Department of Veterans Affairs can exercise signifi-
cant leverage in procurement deals); cf. Daniels, supra note 152, at 493 (discuss-
ing the Department of Labor’s successful use of threats to debar firms from
federal contracts in order to secure compliance with equal employment opportu-
nity requirements).
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challenge rather than accede to its demands, the FDA invariably ar-
gued that the controversy was not ripe for review.164  If a company
voluntarily corrected the violations of federal law alleged in a warning
letter, whether or not accompanied by a threatened procurement
freeze, then it lost any chance to challenge the legal basis for the
FDA’s objections.
Historically, the FDA lacked the statutory authority to order a re-
call of potentially dangerous products subject to its regulatory juris-
diction.165  Over the last few decades, Congress gradually has
expanded the agency’s authority to demand such corrective actions,166
though still not with regard to drugs.167  In the absence of delegated
power, the agency has had to encourage voluntary recalls, and long
ago it promulgated detailed regulations setting forth its recall proce-
dures and policies.168
164. See, e.g., Dietary Supplement Coalition, Inc. v. Kessler, 978 F.2d 560, 563 (9th
Cir. 1992); Prof’ls & Patients for Customized Care v. Shalala, 847 F. Supp. 1359,
1365 (S.D. Tex. 1994), aff’d, 56 F.3d 592, 599 (5th Cir. 1995); Estee Lauder, Inc. v.
FDA, 727 F. Supp. 1, 5 (D.D.C. 1989); see also Boxhorn, supra note 161, at 759–62
(discussing these and more recent decisions). But see Wash. Legal Found. v.
Kessler, 880 F. Supp. 26, 29–30, 34–36 (D.D.C. 1995) (holding that a challenge to
the FDA’s unofficial policy against drug industry sponsorship of scientific sympo-
sia was ripe for review based in part on warning letters alleging the unlawful
promotion of off-label uses at such meetings).  Only once did a court hold that
such a challenge was justiciable on the basis of an interim procurement freeze.
See Den-Mat Corp. v. United States, 1992 U.S. Dist. LEXIS 12233, at *13 (D. Md.
Aug. 17, 1992) (“Such action by the FDA would effectively ‘seize’ all products that
normally would be sold to federal agencies.”).  The court also expressed concern
that “the FDA may have targeted Den-Mat . . . for a publicity campaign designed
to coerce Den-Mat (and others) into complying with the agency’s decision.” Id. at
*14.
165. See Nat’l Confectioners Ass’n v. Califano, 569 F.2d 690, 694–95 (D.C. Cir. 1978);
United States v. Superpharm Corp., 530 F. Supp. 408, 410 (E.D.N.Y. 1981);
United States v. C.E.B. Prods., Inc., 380 F. Supp. 664, 667–72 (N.D. Ill. 1974).
But cf. United States v. K-N Enter., Inc., 461 F. Supp. 988, 990–91 (N.D. Ill. 1978)
(reading the FDCA broadly as authorizing a court-ordered recall of adulterated
drugs).  In recent years, however, courts have construed the FDA’s power to re-
quest injunctive relief more broadly to include remedies not delineated in the
statute. See, e.g., United States v. Rx Depot, Inc., 438 F.3d 1052, 1058–63 (10th
Cir. 2006); United States v. Lane Labs-USA Inc., 427 F.3d 219, 233–36 (3d Cir.
2005) (upholding a district court order that the seller of unapproved new drugs
pay restitution to consumers).
166. See, e.g., FDA Food Safety Modernization Act, Pub. L. No. 111-353, § 206, 124
Stat. 3885, 3940–44 (2011) (codified at 21 U.S.C. § 350l (2012)); Safe Medical De-
vices Act of 1990, Pub. L. No. 101-629, § 8, 104 Stat. 4520 (codified at 21 U.S.C.
§ 360h(e) (2012)).
167. See Eleanor G. Tennyson, Note, A “Phantom Recall” Does Not Comport with
FDA’s Regulatory Practice—or Does It?: The Need for More Stringent Mandatory
Reporting in FDA Matters, 97 IOWA L. REV. 1839, 1843–44, 1852–53 (2012).
168. See Final Rule, Recalls (Including Product Corrections)—Guidelines on Policy,
Procedures, and Industry Responsibilities, 43 Fed. Reg. 26,202, 26,218 (June 16,
1978) (codified at 21 C.F.R. pt. 7(c) (2014)); see also 21 C.F.R. § 7.40(a) (“This
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This strategy has succeeded because firms know that a failure to
cooperate with an agency request would invite more draconian en-
forcement measures authorized by statute.169  Because, however,
these necessitate judicial proceedings (and DOJ concurrence), the is-
suance of adverse publicity may represent a still more effective way of
prompting action.170  Companies often prefer a voluntary recall be-
cause it allows them to exercise greater control over the nature and
extent of public notification about any hazards associated with their
particular product.171
The FDCA expressly authorizes the issuance of adverse publicity,
though only in limited circumstances.172  Even then, targets of a nega-
tive information campaign often have no meaningful opportunity to
[subpart] recognize[s] the voluntary nature of recall by providing guidelines so
that responsible firms may effectively discharge their recall responsibilities.”).
169. See 21 C.F.R. § 7.40(c) (“Seizure, multiple seizure, or other court action is indi-
cated when a firm refuses to undertake a recall requested by the FDA.”); Pro-
posed Rule, Recall Policy and Procedures, 41 Fed. Reg. 26,924, 26,924 (June 30,
1976) (“While the act does not specifically mention recalls, the statutory sanc-
tions available to FDA have a vital role in a firm’s willingness to recall and sup-
port the development of recall as a major FDA regulatory tool.”); see also Daniels,
supra note 152, at 449 (“[A]gencies often use regulatory nukes by aiming the
nuke instead of launching it, . . . mak[ing] regulatory nukes much more powerful
than their launch rate would suggest.”).
170. See Ernest Gellhorn, Adverse Publicity by Administrative Agencies, 86 HARV. L.
REV. 1380, 1408 (1973) (“Since [recalls] cannot be required by law, the FDA en-
sures compliance by threatening seizure, injunction, and the issuance of public-
ity.  Of these, the threat of publicity is usually the most potent persuader.”); id. at
1415 (noting that the FDA apparently “cannot resist the temptation of using
[public] warnings to operate an extrastatutory recall program”).  In effect, the
government threatens to engage in product disparagement in order to shame the
seller into altering its behavior. Cf. Lars Noah, The Imperative to Warn: Disen-
tangling the “Right to Know” from the “Need to Know” About Consumer Product
Hazards, 11 YALE J. ON REG. 293, 398 (1994) (“[W]arning requirements occasion-
ally represent a surreptitious form of regulation, for instance, to encourage de-
sign modifications or product reformulations without directly mandating the
desired changes.”).  For an excellent recent treatment of this issue, see Nathan
Cortez, Adverse Publicity by Administrative Agencies in the Internet Era, 2011
BYU L. REV. 1371.
171. See Mary Olson, Substitution in Regulatory Agencies: FDA Enforcement Alterna-
tives, 12 J.L. ECON. & ORG. 376, 385–86 (1996); see also id. at 390 (noting con-
cerns about FDA retaliation against uncooperative firms).
172. See 21 U.S.C. § 375(b) (2012) (“The Secretary may also cause to be disseminated
information regarding food, drugs, devices, or cosmetics in situations involving,
in the opinion of the Secretary, imminent danger to health or gross deception of
the consumer.”); see also Ajay Nutrition Foods, Inc. v. FDA, 378 F. Supp. 210,
216–19 (D.N.J. 1974) (refusing to enjoin adverse publicity issued by the FDA),
aff’d mem., 513 F.2d 625 (3d Cir. 1975); Hoxsey Cancer Clinic v. Folsom, 155 F.
Supp. 376, 377–78 (D.D.C. 1957) (same).  For a recent example of an undoubtedly
defensible use of this power, see Denise Grady, F.D.A. Discourages Procedure in
Uterine Surgery, N.Y. TIMES, Apr. 18, 2014, at A13 (“The devices, known as
morcellators, have been widely used in laparoscopic operations to remove fibroid
tumors from the uterus . . . .  The action on Thursday does not take them off the
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respond to the charges or seek judicial review.173  In recognition of the
risk of improper use, the FDA once proposed a rule to limit the issu-
ance of such publicity.174  The agency never finalized this proposal,
and it continues to rely on explicit or implicit threats of disseminating
bad press as a method of encouraging voluntary compliance with its
recall and other demands.175  For instance, although the FDA has no
business trying to influence decisions about what price companies
charge for products subject to its jurisdiction,176 the agency recently
used public threats to do just that after a manufacturer introduced a
new drug at what seemed like an exorbitant price.177
market or ban their use, but ‘discourages’ doctors from using them in hysterecto-
mies or fibroid surgery.”)
173. See Cortez, supra note 170, at 1383–84, 1386–87, 1441–54; id. at 1453 (conclud-
ing that agencies “enjoy virtually boundless discretion to brandish adverse pub-
licity”); Gellhorn, supra note 170, at 1424 (“Publicity is quicker and cheaper; it is
not presently subject to judicial review or other effective legal control; and it in-
volves the exercise of pure administrative discretion.”); id. at 1426 (“Because ad-
verse publicity is usually a deprivation not subject to effective judicial control, it
should usually be a sanction of last, not first, resort.”); id. at 1441 (“Adverse
agency publicity is a powerful and often unruly nonlegal sanction.”); Wu, supra
note 155, at 1856–57 (discussing the hazards of “conviction by press release”).
174. See Proposed Rule, Publicity Policy, 42 Fed. Reg. 12,436, 12,440–41 (Mar. 4,
1977), withdrawn, 56 Fed. Reg. 67,440, 67,446 (Dec. 30, 1991); see also 45 C.F.R.
pt. 17 (2013) (HHS policy governing the use of publicity); cf. 21 C.F.R.
§ 10.115(b)(3) (2014) (excluding from GGPs “agency reports, general information
documents provided to consumers or health professionals, speeches, journal arti-
cles and editorials, media interviews, [and] press materials”).  Instead, the FDA
has issued guidance governing its use of adverse publicity. See Cortez, supra
note 170, at 1406–07.
175. See Cortez, supra note 170, at 1375–76, 1381–82, 1409–15; id. at 1413 (finding
that “the FDA issued 1542 press announcements between 2004 and 2010, equat-
ing to almost one every business day” and that 30% of these qualified as individu-
alized, negative, and preliminary).
176. “One may well ask how far an agency might go in conditioning licenses.  In addi-
tion to postmarketing studies and the waiver of hearing rights, for example, could
the FDA condition product approvals on agreements not to engage in broadcast
advertising or not to raise drug prices faster than the rate of inflation?”  Noah,
supra note 151, at 883; see also id. (“Could the Agency demand waivers of patent
rights or promises to contribute some percentage of profits to a public health
agency (or perhaps the Republican National Committee)?”); id. at 933 (“[T]he
FDA presumably understands that it cannot condition product approvals on vol-
untary price controls or charitable contributions, even though Congress has not
expressly prohibited such demands.”).
177. After it received FDA approval for the preterm labor drug Makena® (hydroxy-
progesterone caproate), which came with seven years of market exclusivity as an
“orphan” drug, K-V Pharmaceutical attracted sharp criticism for deciding to
charge $1,500 per dose (approximately $30,000 total during the course of a preg-
nancy) because previously available compounded versions had sold for no more
than $20 per dose. See Rob Stein, Price Tag Soars on Preterm Birth Drug, WASH.
POST, Mar. 29, 2011, at A1 (adding that an FDA official suggested that it might
approve a generic version of the same drug for a different indication, which would
then allow physicians to use it off-label).  In a thinly veiled effort to pressure the
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B. Offers/Threats in the Licensing Context
Product licensing gives the FDA even greater leverage for ex-
tracting concessions from sellers.178  In 1996, for instance, the agency
approved Procter & Gamble’s food additive petition for the non-caloric
fat substitute olestra for use in certain snack foods.179  Nearly twenty-
five years had elapsed between the company’s initial contacts with
agency officials and final approval, and Procter & Gamble spent more
than $200 million in the product development process.180  Indeed, the
FDA approved olestra just days before the expiration of the company’s
previously extended patents.181  The final regulation conditioned use
of the additive on special labeling, vitamin fortification, and the sub-
mission of follow-up reports to allow for further review.182
The requirement for postmarket surveillance represented one of
the most curious features of the approval.  The regulation itself did
not mandate further testing by the petitioner; it only provided that the
FDA “will review and evaluate all data and information bearing on
the safety of olestra received by the agency.”183  In the preamble ac-
companying the regulation, however, the agency explained that “as a
manufacturer to lower its price, the agency issued a press release indicating that
it would continue to tolerate pharmacy compounding of the drug. See Rob Stein,
FDA Won’t Obstruct Cheap Alternative to Makena, WASH. POST, Mar. 31, 2011, at
A5; see also K-V Pharm. Co. v. FDA, 889 F. Supp. 2d 119, 132–40 (D.D.C. 2012)
(dismissing as unreviewable a challenge to this exercise of enforcement discre-
tion); Harris, supra note 97, at A1 (reporting that the White House had forced the
FDA to issue this statement); Andrew Zajac, Pregnancy Drug’s Price Reduced,
L.A. TIMES, Apr. 2, 2011, at AA2 (reporting a revised but still controversial price
of $690 per dose); cf. Lars Noah, Treat Yourself: Is Self-Medication the Prescrip-
tion for What Ails American Health Care?, 19 HARV. J.L. & TECH. 359, 385–86 &
n.141 (2006) (hypothesizing this sort of a stunt).
178. It certainly provides agencies with a powerful mechanism for securing adherence
to nonbinding announcements. See Anthony, supra note 9, at 1340, 1372; Robert
A. Anthony, “Well, You Want the Permit, Don’t You?” Agency Efforts to Make Non-
legislative Documents Bind the Public, 44 ADMIN. L. REV. 31 (1992).
179. See Food Additives Permitted for Direct Addition to Food for Human Consump-
tion; Olestra, 61 Fed. Reg. 3118, 3172 (Jan. 30, 1996) (codified as amended at 21
C.F.R. § 172.867(c) (2014)) [hereinafter Olestra Rule]; see also Lars Noah & Rich-
ard A. Merrill, Starting from Scratch?: Reinventing the Food Additive Approval
Process, 78 B.U. L. REV. 329, 413–21 (1998) (elaborating on this case study).
180. See Marian Burros, Intensifying Debate on a Fat Substitute, N.Y. TIMES, Jan. 17,
1996, at C1.
181. See Sally Squires, FDA Decision Nears on Fat Substitute, WASH. POST, Jan. 23,
1996, at F8.  Upon approval, the company became eligible for limited patent term
restoration. See Notice, Determination of Regulatory Review Period for Purposes
of Patent Extension; Olean, 62 Fed. Reg. 763 (Jan. 6, 1997); Raju Narisetti, Anat-
omy of a Food Fight: The Olestra Debate, WALL ST. J., July 31, 1996, at B1 .
182. See 21 C.F.R. § 172.867(d)–(f) (2014).
183. Id. § 172.867(f) (adding that the FDA “will present such data, information, and
evaluation to the agency’s Food Advisory Committee within 30 months of the ef-
fective date of this regulation,” and then “will initiate any appropriate regulatory
proceedings”).  Eight years later, after conducting this further review, the agency
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condition of approval, Procter and Gamble is to conduct the studies
that it has identified in its letter to FDA,”184 and it warned that, “if
Procter and Gamble does not conduct the identified studies and does
not conduct them according to the articulated timetable, FDA will con-
sider the approval set forth in this document to be void ab initio and
will institute appropriate proceedings.”185
This threat was remarkable insofar as it treated the food additive
approval as a private license rather than a public regulation available
(subject only to patent limitations) to any firm wishing to manufacture
and sell the additive.186  The FDA’s threat also seemingly ignored the
procedures specified by Congress for withdrawing an approval.187
The agency responded that its postmarket surveillance condition was
“not without precedent,” citing the more limited data collection re-
quirement imposed fifteen years earlier on the manufacturer of the
food additive aspartame,188 but this also had reflected a nominally
voluntary undertaking by the sponsor.189
amended the rule. See Final Rule, Food Additives Permitted for Direct Addition
to Food for Human Consumption; Olestra, 69 Fed. Reg. 29,432 (May 24, 2004).
184. Olestra Rule, 61 Fed. Reg. at 3168 (“Procter and Gamble has notified FDA that
the company will be conducting additional studies of olestra exposure (both
amounts consumed and patterns of consumption) and the effects of olestra con-
sumption . . . .”); see also U.S. GEN. ACCT. OFFICE, GAO/RCED-93-142, FOOD
SAFETY AND QUALITY: INNOVATIVE STRATEGIES MAY BE NEEDED TO REGULATE NEW
FOOD TECHNOLOGIES  61 (1993) [hereinafter GAO FOOD ADDITIVE REPORT] (Ac-
cording to one official, the “FDA may try to negotiate requirements for firms to
conduct postmarket surveillance, including the collection and reporting of data on
dietary use and on any adverse effects, as a condition for approving novel macro-
ingredients as food additives.”).
185. Olestra Rule, 61 Fed. Reg. at 3169.  The preamble provided little information
about the nature of this correspondence, though the letter from the company ref-
erenced by the agency—dated one month after the close of the public comment
period and less than one week before publication of the approval—suggested last
minute negotiations had taken place.
186. See GAO FOOD ADDITIVE REPORT, supra note 184, at 27 (“Unlike approvals for
new drugs, food additives regulations are not licenses.  Once FDA has issued a
regulation specifying the uses and conditions of use for a food additive, any com-
pany is free to market the additive as long as the additive is in compliance with
the regulation and is not patented.”).
187. See 21 U.S.C. § 348(h) (2012); 21 C.F.R. § 171.130 (2014).
188. Olestra Rule, 61 Fed. Reg. at 3169.  The final decision approving aspartame in-
cluded the following additional condition: “Searle is to monitor the actual use
levels of aspartame and to provide such information on aspartame’s use to the
Bureau of Foods as the Bureau may deem necessary by an order, in the form of a
letter, to Searle.”  Notice, Aspartame: Commissioner’s Final Decision, 46 Fed.
Reg. 38,285, 38,303 (July 24, 1981).
189. See GAO FOOD ADDITIVE REPORT, supra note 184, at 61 (“In at least one instance,
FDA has been able to obtain voluntary postmarket surveillance for a food addi-
tive (Aspartame, an artificial sweetener) as part of the approval process for this
substance.  However, FDA does not have the statutory authority to require sur-
veillance for food products, as it does for human drugs . . . .”).
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Even more so than it does in the case of food additives, the FDA
carefully reviews all new drug products prior to marketing.  Until re-
cently, the FDCA made no mention of postmarket (so-called “Phase
IV”) study requirements,190 but the agency long ago issued regula-
tions governing such clinical trials.191  As a condition of product ap-
proval, the FDA often has encouraged applicants to undertake
postapproval research,192 though it has done a poor job of holding
pharmaceutical manufacturers to these promises.193  In 1997, Con-
gress authorized such requirements, though only for drugs eligible for
“fast track” review.194  Ten years later, it amended the statute to al-
low for the routine imposition of postapproval study requirements.195
In 1992, in response to complaints about excessive delays in ap-
proving AIDS drugs, the agency promulgated regulations to establish
an accelerated approval procedure for new drugs and biologics in-
tended to treat serious or life-threatening illnesses.196  Before approv-
ing a new drug, the FDA must find that it is both safe and effective,
but, under the accelerated approval procedures, it accepted weaker ev-
idence of effectiveness than normally required.197  If a pharmaceutical
190. See Robert L. Fleshner, Post-Marketing Surveillance of Prescription Drugs: Do
We Need to Amend the FDCA?, 18 HARV. J. ON LEGIS. 327 (1981).
191. See Final Rule, Approved New Drugs That Require Continuation of Long-Term
Studies, Records, and Reports; Listing of Levodopa, 37 Fed. Reg. 201 (Jan. 7,
1972) (codified as amended at 21 C.F.R. § 310.303(a) (2014)).
192. See Charles Steenburg, The Food and Drug Administration’s Use of Postmarket-
ing (Phase IV) Study Requirements: Exception to the Rule?, 61 FOOD & DRUG L.J.
295, 325–27 (2006).  The Centers for Medicare and Medicaid Services (CMS) have
twisted different arms to encourage postapproval studies. See Lars Noah, Co-
erced Participation in Clinical Trials: Conscripting Human Research Subjects, 62
ADMIN. L. REV. 329, 331–35 & n.7, 342–66 (2010) (criticizing CMS for using its
leverage to persuade Medicare beneficiaries to “volunteer” for medical research);
id. at 331–32 & nn.10–11 (explaining that the agency used guidance documents
to announce this policy).
193. See Gardiner Harris, Drug Makers Remain Years Behind on Testing Approved
Medicines, Report Finds, N.Y. TIMES, Oct. 27, 2009, at A18.
194. See Food and Drug Administration Modernization Act, Pub. L. No. 105-115,
§ 112(a) (FDCA § 506(b)(2)(A)), 111 Stat. 2296, 2309 (1997) (codified at 21 U.S.C.
§ 356(b)(2)(A) (2012)).
195. See Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85,
§ 901(a) (FDCA § 505(o)), 121 Stat. 823, 923 (codified at 21 U.S.C. § 355(o)
(2012)); see also infra note 214 and accompanying text (summarizing restrictions
on exercising this new power).
196. See Final Rule, New Drug, Antibiotic, and Biological Drug Product Regulations;
Accelerated Approval, 57 Fed. Reg. 58,942, 58,958 (Dec. 11, 1992) (codified at 21
C.F.R. pts. 314(H), 601(E) (2014)) [hereinafter Accelerated Approval Rule].
197. For instance, the FDA will accept evidence of drug effectiveness in attaining “sur-
rogate endpoints” (e.g., reductions in CD4 cell counts or tumor shrinkage) in lieu
of the more difficult to prove “clinical endpoints” (e.g., improved survival). See 21
C.F.R. §§ 314.510, 601.41 (2014); Accelerated Approval Rule, 57 Fed. Reg. at
58,943–44.  Approval predicated on surrogate endpoints requires that the appli-
cant agree to conduct postmarketing studies relating to the clinical endpoints.
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company wanted to utilize this expedited licensing procedure, it had to
agree to several conditions on approval not originally authorized by
Congress.  For example, an applicant would have to accept any neces-
sary postmarketing restrictions, including distribution only through
certain medical facilities or by specially-trained physicians, distribu-
tion conditioned on the performance of specified medical procedures,
and advance submission of all promotional materials for FDA re-
view.198  At the time that the agency issued the rule, however, the
governing statute did not authorize the imposition of any of these
conditions.199
Moreover, the FDA demanded that a company waive its statutory
right to demand an evidentiary hearing in the event that the agency
later chose to withdraw the approval.200  In response to industry com-
plaints about such conditions, the FDA explained that any “applicants
objecting to these procedures may forego approval under these regula-
tions and seek approval under the traditional approval process.”201
With potentially millions of dollars in revenue foregone for each addi-
tional month awaiting approval,202 however, eligible drug companies
198. See 21 C.F.R. §§ 314.520(a), 314.550, 601.42(a), 601.45.
199. See supra note 157 (describing limits on the power to preclear advertising); infra
note 206 (discussing limits on the power to restrict distribution).  The FDA re-
sponded that the statute provided it with sufficient flexibility to impose these
various conditions for accelerated approvals. See Accelerated Approval Rule, 57
Fed. Reg. at 58,949, 58,951 (alluding to the “spirit” of the statute); id. at
58,953–54 (citing its broad rulemaking authority); see also Jeffrey E. Shuren, The
Modern Regulatory Administrative State: A Response to Changing Circum-
stances, 38 HARV. J. ON LEGIS. 291, 308–15 (2001) (defending these initiatives).
200. See 21 C.F.R. §§ 314.530, 601.43 (providing the applicant with only an informal
hearing prior to revocation).
201. Accelerated Approval Rule, 57 Fed. Reg. at 58,955.  The FDA also explained that
no court had interpreted the statute as requiring a formal evidentiary hearing
before withdrawing approval, but that its own regulations provided for such a
hearing. See id.  Although the agency may utilize a summary judgment proce-
dure to deny hearing requests when it withdraws its approval for a new drug
approval, see Weinberger v. Hynson, Westcott & Dunning, Inc., 412 U.S. 609,
620–22 (1973), it must provide a hearing when genuine issues are in dispute, see
id. at 623; Edison Pharm. Co. v. FDA, 513 F.2d 1063, 1072 (D.C. Cir. 1975); Ster-
ling Drug, Inc. v. Weinberger, 503 F.2d 675, 680–83 (2d Cir. 1974).  The FDA also
argued that the less formal hearing procedure that it provided for withdrawals of
accelerated approvals would give the applicant adequate notice and opportunity
to be heard. See Accelerated Approval Rule, 57 Fed. Reg. at 58,955.
202. See User Fees for Prescription Drugs: Hearing Before the Subcomm. on Health
and the Environment of the H. Comm. on Energy and Commerce, 102d Cong. 10
(1992) (statement of David A. Kessler, Commissioner, FDA) (“For a drug that
raises $200 million a year in annual sales, assuming an 80 percent gross margin,
every additional month of delay the Agency takes to review an application would
cost the company about $10 million in lost opportunity.”); Joseph A. DiMasi et al.,
The Price of Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH
ECON. 151 (2003); Peter Landers, Cost of Developing a New Drug Increases to
About $1.7 Billion, WALL ST. J., Dec. 8, 2003, at B4.
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could not afford to decline the invitation to make use of these acceler-
ated procedures, and the industry never challenged the rules in court.
To its credit, the agency used rulemaking to create this mechanism,
and, five years later, Congress belatedly authorized these special pro-
cedures for what it called “fast track” review.203
The FDA also has shown growing interest in developing more tai-
lored risk management strategies for non-critical pharmaceuticals.
These efforts might include restricting distribution to certain special-
ists,204 patient informed consent requirements, structured
postmarket surveillance, and mandatory concomitant therapy or mon-
itoring.205  In addition, the agency might seek to prohibit certain off-
label uses, perhaps in those situations where the labeling specifically
contraindicates a use.  Before 2007, serious questions existed about
the FDA’s power to impose such restrictions,206 but the agency often
managed to encourage pharmaceutical manufacturers to accept such
limitations as a condition of product approval.207  Congress subse-
203. See Food and Drug Administration Modernization Act, Pub. L. No. 105-115,
§ 112(a) (FDCA § 506), 111 Stat. 2296, 2309 (1997) (codified at 21 U.S.C. § 356
(2012)).  This seems like a recurring pattern over the last few decades: the FDA
tries something that arguably exceeds the bounds of its delegated authority, and
Congress later endorses the effort by granting the agency explicit authority that
it previously lacked though subject to limitations.
204. See, e.g., Lars Noah, Assisted Reproductive Technologies and the Pitfalls of Un-
regulated Biomedical Innovation, 55 FLA. L. REV. 603, 654 (2003) (suggesting
that only reproductive endocrinologists enjoy access to fertility drugs); Scott B.
Markow, Note, Penetrating the Walls of Drug-Resistant Bacteria: A Statutory Pre-
scription to Combat Antibiotic Misuse, 87 GEO. L.J. 531, 546–47 (1998) (sug-
gesting that only infectious disease specialists in hospitals be permitted to use
the latest antibiotics).
205. See Notice of Availability, Guidances for Industry on Premarketing Risk Assess-
ment; Development and Use of Risk Minimization Action Plans; and Good
Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, 70 Fed.
Reg. 15,866 (Mar. 29, 2005).
206. See Am. Pharm. Ass’n v. Weinberger, 377 F. Supp. 824, 831 (D.D.C. 1974) (invali-
dating FDA restrictions on the distribution of methadone as a condition of ap-
proval), aff’d, 530 F.2d 1054 (D.C. Cir. 1976) (per curiam); Mark A. Hurwitz,
Note, Bundling Patented Drugs and Medical Services: An Antitrust Analysis, 91
COLUM. L. REV. 1188, 1192–95 (1991); see also Anna Wilde Mathews & Leila Ab-
boud, FDA Approves Generic OxyContin, WALL ST. J., Mar. 24, 2004, at A3 (“[T]he
FDA has never limited any opioid to certain pharmacies, and agency officials say
they don’t have the authority to block certain physicians from prescribing a
drug.”).
207. See Lars Noah, Ambivalent Commitments to Federalism in Controlling the Prac-
tice of Medicine, 53 U. KAN. L. REV. 149, 153, 188–91 (2004).  One former FDA
official (who had just left his post as a deputy commissioner) explained that risk-
management plans “already guide the use of about 30 marketed drugs as part of
‘voluntary’ arrangements with drug companies.”  Scott Gottlieb, Op-Ed., Prescrip-
tion for Trouble, WALL ST. J., Mar. 6, 2007, at A19; see also Scott Gottlieb, Drug
Safety Proposals and the Intrusion of Federal Regulation into Patient Freedom
and Medical Practice, 26 HEALTH AFF. 664, 666 (2007) (elaborating); Lars Noah,
Challenges in the Federal Regulation of Pain Management Technologies, 31 J.L.
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quently did authorize the imposition of many such restrictions,208
though subject to various constraints that continue to make the old
voluntary approach attractive to the agency.
In some cases, physicians must register with the manufacturer—
attesting that they understand the risks and benefits of a particular
drug—before they may prescribe it.209  For instance, when it approved
Thalomid® (thalidomide) for the treatment of leprosy patients, the
FDA conditioned approval on extremely strict marketing controls be-
cause of the serious risk of birth defects: distribution only through
specially registered physicians and pharmacists, and tracking of pa-
tients who must agree to use two forms of contraception and undergo
frequent pregnancy tests.210  The agency secured comparable distri-
MED. & ETHICS 55, 63 (2003) (noting that, in trying to encourage the manufac-
turer of OxyContin® to restrict distribution to pain management specialists, the
Drug Enforcement Administration (DEA) “threatened to slash the company’s an-
nual production quota by approximately 95 percent”).  The DEA has used threats
against physicians in an attempt to undermine state laws that liberalized access
to controlled substances. See Interpretive Rule, Dispensing of Controlled Sub-
stances to Assist Suicide, 66 Fed. Reg. 56,607, 56,608 (Nov. 9, 2001); Notice, Ad-
ministration Response to Arizona Proposition 200 and California Proposition 215,
62 Fed. Reg. 6164, 6164 (Feb. 11, 1997) (threatening the withdrawal of prescrib-
ing licenses, exclusion from participation in Medicare and Medicaid, and criminal
prosecution of physicians who merely recommended marijuana to their patients
as authorized under state law).  In both instances, courts invalidated these ef-
forts. See Gonzales v. Oregon, 546 U.S. 243, 272–75 (2006); Conant v. Walters,
309 F.3d 629, 639 (9th Cir. 2002).
208. See Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85,
tit. IX, 121 Stat. 823, 922.  In implementing this authority, the agency announced
that previously accepted voluntary restrictions thereafter would be considered to
comply with this provision. See Identification of Drug and Biological Products
Deemed to Have Risk Evaluation and Mitigation Strategies for Purposes of the
Food and Drug Administration Amendments Act of 2007, 73 Fed. Reg. 16,313,
16,314 tbl.1 (Mar. 27, 2008) (identifying sixteen such products).
209. See Francesca Lunzer Kritz, Still Irritable, Still Waiting: After Return to Market,
Lotronex Can Be Hard to Get, WASH. POST, Feb. 11, 2003, at F1 (discussing re-
strictions on access to a drug used for the treatment of irritable bowel syndrome,
and explaining that similar physician registration requirements apply to felba-
mate (used for epilepsy) and clozapine (used for schizophrenia)).
210. See Rita Rubin, Thalidomide Could Guide Use of Drugs That Risk Birth Defects,
USA TODAY, July 22, 1998, at 7D; see also Sheryl Gay Stolberg, Thalidomide Ap-
proved to Treat Leprosy, with Other Uses Seen, N.Y. TIMES, July 17, 1998, at A1
(“If any doctors or pharmacists refuse to comply with the distribution rules, their
privileges to prescribe or dispense the drug might be revoked.”); Jamie Talan,
Thalidomide’s Legacy, WASH. POST, Jan. 4, 2000, at F10 (reporting that physi-
cians who prescribe the drug receive from the manufacturer an “education kit,
including a consent form to be signed by both doctor and patient”).
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bution restrictions in connection with Accutane® (isotretinoin)211 and
Mifeprex® (mifepristone).212
When Congress has, however, empowered the FDA to impose par-
ticular requirements but subject them to various procedural and sub-
stantive restrictions, the agency should not sidestep these limitations
through the simple expedient of encouraging the voluntary acceptance
of such conditions on approval.  For instance, the authority granted to
the FDA in 2007 to adopt various distribution controls—called “risk
evaluation and mitigation strategy” (REMS) requirements—provided,
among other things, for advisory committee review, issuance of gui-
dance, posting of approval letters or orders that impose REMS, elabo-
rate dispute resolution procedures, and public meetings.213  Similarly,
under the postapproval studies provision added in 2007, the agency
cannot demand such trials unless, among other things, it determines
that less intensive risk surveillance methods will not suffice, the spon-
sor is granted an opportunity to seek resolution of any disputes about
211. See Lars Noah, Too High a Price for Some Drugs?: The FDA Burdens Reproduc-
tive Choice, 44 SAN DIEGO L. REV. 231, 233–39 (2007); see also id. at 240–58 (ques-
tioning the constitutionality of mandatory contraception as a condition of access
to teratogenic drugs).
212. See Lars Noah, A Miscarriage in the Drug Approval Process?: Mifepristone Em-
broils the FDA in Abortion Politics, 36 WAKE FOREST L. REV. 571, 583–86 (2001);
id. at 581–82 (“Mifepristone’s eligibility to use such [accelerated review] proce-
dures remains something of a mystery: the drug did not provide the type of thera-
peutic benefit over existing treatments for a serious illness that the regulations
contemplated as justifying an expedited approval process. . . .  Apparently the
agency took this route so that it could better justify imposing otherwise unautho-
rized restrictions on the use and distribution of the drug . . . .”); Gina Kolata, U.S.
Approves Abortion Pill, N.Y. TIMES, Sept. 29, 2000, at A1 (“A woman will be given
written instructions . . . , and her doctor must sign a statement saying they have
read the instructions and will comply with them exactly.”).  For the most part,
however, these restrictions have not been enforced. See Marc Kaufman, Death
After Abortion Pill Reignites Safety Debate, WASH. POST, Nov. 3, 2003, at A3.
213. See Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85,
§ 901(b) (FDCA § 505-1(f)–(h)), 121 Stat. 823, 930–37 (codified at 21 U.S.C. § 355-
1(f)–(h) (2012)); Jennifer L. Bragg & Maya P. Florence, Life with a REMS: Chal-
lenges and Opportunities, 13 J. HEALTH CARE L. & POL’Y 269, 269–75 (2010); An-
drew Wilson & Christopher-Paul Milne, FDA’s Risk Evaluation and Mitigation
Strategies (REMS): Effective and Efficient Safety Tools or Process Poltergeist, 66
FOOD & DRUG L.J. 569, 570–71, 578 tbl.2, 583–85 (2011).  For instance, the FDA
initiated such a process for narcotic analgesics. See Notice of Availability, Draft
Blueprint for Prescriber Education for Long-Acting/Extended-Release Opioid
Class-Wide Risk Evaluation and Mitigation Strategy, 76 Fed. Reg. 68,766 (Nov.
7, 2011).  Evidently based on some of the feedback that it received, the agency
decided not to proceed with this idea. See Barry Meier, F.D.A. Won’t Order Doc-
tors to Get Pain-Drug Training, N.Y. TIMES, July 10, 2012, at B2; see also Hilary
Homenko, Note, Rehabilitating Opioid Regulation: A Prescription for the FDA’s
Next Proposal of an Opioid Risk Evaluation and Mitigation Strategy (REMS), 22
HEALTH MATRIX 273, 275–76, 294–96 (2012) (explaining that an earlier proposal
had fared poorly at an advisory committee meeting); id. at 292–94 (noting that
the FDA has imposed REMS for narcotic analgesics on an ad hoc basis instead).
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the imposition of such a requirement, and the necessary determina-
tions are made only by division directors or higher-level officials.214
Arm-twisting would improperly allow the FDA to secure voluntary
distribution controls or postapproval studies without abiding by the
limitations crafted by Congress.  At the very least, the agency should
announce its policies openly rather than leave them to ad hoc negotia-
tions largely hidden from external scrutiny.215
IV. CONCLUSION
For a relatively small agency with a lot on its plate,216 the FDA’s
reliance on procedural short cuts should come as no great surprise.
Guidance documents clearly have a place in the portfolio of any
agency, but the FDA has used this format for policy announcements
that previously would have emerged after notice-and-comment
rulemaking.  In some respects, Congress has endorsed and further en-
couraged this development, but it also has sought to proceduralize and
put the brakes on guidance-making at the FDA,217 leading the agency
to look for ways to escape even these limited constraints.  Moreover,
214. See Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85,
§ 901(a) (FDCA § 505(o)(3)(D), (F), (o)(5)), 121 Stat. 823, 923–24, 926 (codified at
21 U.S.C. § 355(o)(3)(D), (F), (o)(5) (2012)).
215. See Noah, supra note 151, at 938–40; see also Cooper, supra note 160, at 843
(“Even when enforcement officials may very well be exceeding their statutory au-
thority or invading constitutionally protected rights (e.g., commercial free
speech), organizations almost always prefer to settle.  In doing so, they give up an
opportunity to obtain a judicial ruling on the agency’s enforcement theories.”); id.
at 844–47 (explaining why agency consent decrees and settlement policies evade
scrutiny by both the judicial and executive branch); id. at 846 (“Judicial review,
therefore, appears not to be an effectual restraint on the power of enforcement
officials to extract concessions in settlements.  Moreover, what is needed much
more than case-by-case post hoc review of individual settlements is advance re-
view of the policies and forms of agreement that shape an enforcement agency’s
settlements generally.”).  For instance, the agency did issue a guidance document
to explain how it would exercise its new authority to require postapproval stud-
ies. See Notice of Availability, Guidance for Industry on Postmarketing Studies
and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food,
Drug, and Cosmetic Act, 76 Fed. Reg. 18,226 (Apr. 1, 2011).
216. See Noah, supra note 1, at 902.
217. Cf. Anthony, supra note 9, at 1317 (warning of “the tendency to overregulate that
is nurtured when the practice of making binding law by guidances, manuals, and
memoranda is tolerated”); id. at 1374 (arguing that “the APA rulemaking re-
quirements impose a salutary discipline . . . [, which] deters casual and sloppy
action, and . . . reduces tendencies toward overregulation or bureaucratic over-
reaching”); Matthew D. McCubbins et al., Structure and Process, Politics and Pol-
icy: Administrative Arrangements and the Political Control of Agencies, 75 VA. L.
REV. 431, 442 (1989) (“Administrative procedures erect a barrier against an
agency carrying out such a [policy change as a] fait accompli by forcing the
agency to move slowly and publicly, giving politicians (informed by their constitu-
ents) time to act before the status quo is changed.”); id. at 481 (same).
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guidance documents represent only the tip of the iceberg, with the
FDA making use of any number of even less formal tools and tech-
niques in order to accomplish its ends.  Perhaps that is neither unex-
pected nor invariably worrisome, but those who keep tabs on this
agency must remain vigilant to guard against the possibility that it
will overuse and abuse these procedural short cuts.
